Record,OAR or Target,Fractions,Intent,Primary Site,Volume,Volume Deviation,PRV,Dose,Dose Deviation,Conversion,α/β,Protocol,Landmark Pub,Importance,Paper #1 Title,Paper #1 Link,Paper #2 Title,Paper #2 Link,Notes
1,Brain,Conventional,General,,Whole,,,50 Gy,,,3,,QUANTEC,,,,,,
2,Brain,Conventional,General,,Partial,,,60 Gy,72 Gy,,3,,QUANTEC,,,,,,Symptomatic necrosis for 60 / 72 / 90 Gy Dmax of < 3→ 5→ 10% (TD 5/5 = 72 Gy)
3,Brain,3,General,,30.2 cc,,,18 Gy,,,3,,HyTEC,,,,Intact Minniti IJROBP '16,http://www.redjournal.org/article/S0360-3016(16)00325-4/fulltext,
4,Brain,5,General,,16 cc,,,25 Gy,,,3,,,,Andruska RTO '20,https://pubmed.ncbi.nlm.nih.gov/33310010/,,,
5,Brain,1,Intact,,10 cc,,,12 Gy,,,3,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,QUANTEC",,,,,,V12 < 5-10 cc with < 20% symptomatic necrosis.
6,Brain,3,Postop,,16.8 cc,,,24 Gy,,,3,,,,Post-op,https://www.ncbi.nlm.nih.gov/pubmed/23683828,,,
7,Brain,1,General,,8.0 cc,8.5 cc,,12 Gy,,,3,,,,Blonigen IJROBP '10,https://www.sciencedirect.com/science/article/pii/S0360301609008566?via%3Dihub,Minniti Rad Onc '11,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108308/pdf/1748-717X-6-48.pdf,"Limit V12 to 8-8.5 cc, otherwise consider hypofractionated treatment"
8,Brain,5,Postop,,0.05 cc,,,33.5 Gy,,,3,,,,Tanenbaum PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/23683828,,,Hot spots within the surgical cavity do not appear to matter.
9,Brain,3,General,,7 cc,,,23 Gy,,,3,,HyTEC,,,,,,
10,Brain,5,General,,10 cc,10.5 cc,,30 Gy,,,3,,,,Faruqi IJROBP '20,https://www.sciencedirect.com/science/article/pii/S0360301619344761?via%3Dihub,Andruska RTO '20,https://pubmed.ncbi.nlm.nih.gov/33310010/,
11,Brain,Conventional,General,,1 cc,,,58 Gy,,,3,,DAHANCA,Should,,,,,
12,Brain,Conventional,General,,Max,,,68 Gy,,,3,,DAHANCA,Should,,,,,
13,Brain,1,General,,50%,,,5 Gy,,,3,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,QUANTEC",,,,,,
14,Brainstem,Conventional,General,,0.03 cc,,,54 Gy,,,2,,QUANTEC,,,,,,Permanent cranial neuropathy or necrosis for < 5% for 59 Gy to 1-10 cc. The risk increases markedly at doses > 64 Gy.
15,Brainstem,Conventional,General,,0.03 cc,,0.3 cm,60 Gy,,,2,RTOG 0825,DAHANCA,Absolute,,,,,
16,Brainstem,Conventional,General,,1 cc,10 cc,,59 Gy,,,2,,QUANTEC,,,,,,
17,Brainstem,1,General,,Max,,,15 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
18,Brainstem,1,General,,1 cc,,,12 Gy,,,2,,QUANTEC,,,,,,12.5 Gy with < 5% permanent cranial neuropathy or necrosis.
19,Brainstem,1,General,,0.1 cc,0.5 cc,,10 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
20,Brainstem,3,General,,Max,,,23.1 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
21,Brainstem,3,General,,0.1 cc,0.5 cc,,18 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
22,Brainstem,5,General,,Max,,,31 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
23,Brainstem,5,General,,0.1 cc,0.5 cc,,23 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
24,Brainstem,10,General,,Max,,,40.5 Gy,,,2,,,,Needs source,,,,
25,Brainstem,10,General,,0.5 cc,,,29.4 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
26,Brainstem,Conventional,General,,Max,,,55 Gy,60 Gy,,2,RTOG 0539,,,,,,,Permanent cranial neuropathy or necrosis for < 5% for 59 Gy to 1-10 cc. The risk increases markedly at doses > 64 Gy.
27,Brainstem,Conventional,General,H&N,0.03 cc,,0.3 cm,52 Gy,,,2,RTOG 1016,,,,,,,
28,Cord,Conventional,General,,Max,,,44.6 Gy,,EQD2,2,,HyTEC,,,,,,Note: Initial SRS/SBRT constraints were based off of 45 Gy conventional fractionation to the cord. This is despite Quantec data that demonstrates ≤ 1% RM for cord Dmax ≤ 54 Gy with conventional fractionation.
29,Cord,Conventional,General,"H&N,NSCLC,Pediatrics",Max,,,45 Gy,,,2,"RTOG 0617,RTOG 1308,ARST 1431",DAHANCA,Absolute,,,,,
30,Cord,BID,Intact,,Max,,,36 Gy,,,2,,,,Turrisi NEJM '99,https://www.nejm.org/doi/10.1056/NEJM199901283400403?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov,,,
31,Cord,BID,Intact,,Max,,,41 Gy,,,2,,,,CALGB 30610/RTOG 0538,,,,
32,Cord,1,General,,Max,,,22.7 Gy,,,2,,HyTEC,,Daly IJROBP '11,https://pubmed.ncbi.nlm.nih.gov/21481724/,,,
33,Cord,Conventional,General,,Max,,0.5 cm,50 Gy,,,2,,DAHANCA,Absolute,,,,,
34,Cord,1,General,,Max,,,12.4 Gy,14 Gy,,2,"RTOG 0915,RTOG 0631","HyTEC,TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,Timmerman,QUANTEC",,,,,,13 Gy with < 1% incidence of myelopathy.
35,Cord,1,General,,0.1 cc,0.35 cc,,10 Gy,,,2,"RTOG 0915,BR002,RTOG 0631","UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,Timmerman",,,,,,
36,Cord,1,General,,10%,,,10 Gy,,,2,RTOG 0631,,,,,,,Percentage applies to subvolume of cord (e.g. 5-6 mm above and below lesion).
37,Cord,1,General,,1.2 cc,,,7 Gy,8 Gy,,2,RTOG 0915,"TG-101,Timmerman",,,,,,
38,Cord,1,General,,1 cc,5 cc,,7 Gy,,,2,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,HyTEC",,,,,,
39,Cord,3,General,,0.1 cc,0.35 cc,,18 Gy,,,2,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,
40,Cord,3,General,,1.2 cc,,,12.3 Gy,13 Gy,,2,BR002,"Timmerman,TG-101",,,,,,
41,Cord,3,General,,10%,,,18 Gy,,,2,,TG-101,,,,,,
42,Cord,3,General,,1 cc,,,12.3 Gy,,,2,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
43,Cord,3,General,,Max,,,22.5 Gy,,,2,BR002,Timmerman,,,,,,
44,Cord,3,General,,Max,,,21.9 Gy,,,2,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
45,Cord,3,General,,Max,,,20.3 Gy,,,2,,HyTEC,,,,,,Note: Initial SRS/SBRT constraints were based off of 45 Gy conventional fractionation to the cord. This is despite Quantec data that demonstrates ≤ 1% RM for cord Dmax ≤ 54 Gy with conventional fractionation.
46,Cord,5,General,,Max,,0.3 cm,32 Gy,,,2,SUNSET,,,,,,,
47,Cord,5,General,,1.2 cc,,,14.5 Gy,15.6 Gy,,2,BR002,"Timmerman,TG-101",,,,,,
48,Cord,5,General,,0.1 cc,0.35 cc,,22 Gy,23 Gy,,2,BR002,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,Timmerman,TG-101",,,,,,
49,Cord,5,General,,Max,,,25.3 Gy,,,2,,HyTEC,,,,,,Note: Initial SRS/SBRT constraints were based off of 45 Gy conventional fractionation to the cord. This is despite Quantec data that demonstrates ≤ 1% RM for cord Dmax ≤ 54 Gy with conventional fractionation.
50,Cord,5,General,,Max,,,28 Gy,,,2,BR002,,,,,,,
51,Cord,5,General,,10%,,,23 Gy,,,2,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,Percentages apply to subvolume of cord (e.g. 5-6 mm above and below lesion).
52,Cord,5,General,,1 cc,,,14.5 Gy,,,2,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
53,Cord,5,General,,Max,,,30 Gy,,,2,"SUNSET,RTOG 0813","TG-101,Timmerman",,,,,,
54,Cord,5,General,,0.5 cc,,,13.5 Gy,,,2,RTOG 0813,,,,,,,
55,Cord,8,General,,Max,,,36.5 Gy,,Extrapolation,2,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
56,Cord,8,General,,0.5 cc,,,32 Gy,,,2,LungTECH,HyTEC,,,,,,
57,Cord,8,General,,Max,,,28 Gy,,,2,,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
58,Cord,8,General,,0.5 cc,,,15.5 Gy,,Extrapolation,2,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
59,Cord,8,General,,Max,,0.3 cm,34 Gy,,,2,SUNSET,,,,,,,
60,Cord,8,General,,0.25 cc,,,27 Gy,,Extrapolation,2,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
61,Cord,8,General,,0.1 cc,,,32 Gy,,,2,SUNSET,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
62,Cord,10,General,,Max,,,40 Gy,,,2,RTOG 0813,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
63,Cord,10,General,,Max,,,34 Gy,,,2,RTOG 0438,,,,,,,
64,Cord,10,General,,0.35 cc,,,29.4 Gy,,,2,,,,,,,,
65,Cord,10,General,,0.1 cc,,,32 Gy,,,2,SUNSET,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
66,Cord,10,General,,1.0 cc,,,35 Gy,,,2,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
67,Cord,10,General,,Max,,0.3 cm,34 Gy,,,2,SUNSET,,,,,,,
68,Cord,10,General,,1.2 cc,,,17.9 Gy,,,2,,,,,,,,
69,Cord,15-16,General,,Max,,0.3 cm,42 Gy,,,2,SUNSET,,,,,,,
70,Cord,15-16,General,Pancreas,Max,,,30 Gy,,,2,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
71,Cord,15-16,General,,Max,,,39.5 Gy,,,2,SUNSET,,,,,,,
72,Cord,15-16,General,,Max,,,33 Gy,35 Gy,,2,,,,NCIC CTV BR.25,https://academic.oup.com/jnci/article/106/8/dju164/910382,,,
73,Cord,15-16,General,,Max,,0.3 cm,40.2 Gy,43.9 Gy,,2,NRG LU004,,,,,,,
74,Cord,15-16,General,,Max,,,36.5 Gy,40.2 Gy,,2,NRG LU004,,,,,,,
75,Cord,Conventional,General,,Max,,,54 Gy,,,2,,QUANTEC,,,,,,"Spinal cord myelopathy rates at 5y for 50 / 54 / 60 / 69 Gy Dmax of 0.2→ 1→ 6→ 50% (TD 5/5 50 Gy for 10 cm length, 55 Gy for 5 cm length; TD 50/5 70 Gy)."
76,Cord,5,General,,0.25 cc,,,22.5 Gy,,,2,RTOG 0813,,,,,,,
77,Cord,2,General,,Max,,0.2 cm,17 Gy,,,2,SC.24,,,,,,,
1167,Cord,Conventional,General,Pediatrics,Max,,,50.4 Gy,,,,AEWS 1031,,,,,,,
78,Optic Chiasm,Conventional,General,,Max,,,54 Gy,55 Gy,,,,"DAHANCA,QUANTEC",Must,,,,,Optic neuropathy rates for 55 / 60 / 60+ Gy Dmax of 3→ 7→ 7-20%.
79,Optic Chiasm,Conventional,General,,Max,,0.3 cm,60 Gy,,,,,"DAHANCA,QUANTEC",Must,,,,,Optic neuropathy rates for 55 / 60 / 60+ Gy Dmax of 3→ 7→ 7-20%.
80,Optic Chiasm,1,General,,Max,,,10 Gy,12 Gy,,,,"TG-101,QUANTEC",,Pollock NS '14,https://academic.oup.com/neurosurgery/article-abstract/75/4/456/2447765?redirectedFrom=fulltext,Mayo IJROBP '10,https://www.sciencedirect.com/science/article/abs/pii/S0360301609032842?via%3Dihub,12 Gy with 10% incidence of optic neuropathy. 12 Gy is considered ballsy.
81,Optic Chiasm,1,General,,0.1 cc,0.2 cc,,8 Gy,,,,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,"Very low < 8 Gy, 12 Gy < 10%, >10% for 12-15 Gy "
82,Optic Chiasm,3,General,,Max,,,17.4 Gy,,,,,TG-101,,,,,,
83,Optic Chiasm,3,General,,0.1 cc,,,15 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
84,Optic Chiasm,3,General,,0.2 cc,,,15.3 Gy,,,,,TG-101,,,,,,
85,Optic Chiasm,5,General,,Max,,,25 Gy,,,,,TG-101,,,,,,
86,Optic Chiasm,5,General,,0.2 cc,,,23 Gy,,,,,TG-101,,,,,,
87,Optic Chiasm,5,General,,0.1 cc,,,22.5 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
88,Optic Chiasm,10,General,,Max,,,32.2 Gy,,,,,,,,,,,
89,Optic Chiasm,10,General,,0.2 cc,,,29.4 Gy,,,,,,,,,,,
90,Optic Chiasm,Conventional,General,Meningioma,0.03 cc,,,54 Gy,56 Gy,,,RTOG 0539,,,,,,,Optic neuropathy rates for 55 / 60 / 60+ Gy Dmax of 3→ 7→ 7-20%.
91,Optic Chiasm,Conventional,General,"Pediatrics,Meningioma",0.03 cc,,,46.8 Gy,54 Gy,,,"RTOG 0539,ARST 1431",,,,,,,Optic neuropathy rates for 55 / 60 / 60+ Gy Dmax of 3→ 7→ 7-20%.
1165,Optic Chiasm,Conventional,General,Pediatrics,100%,,,54 Gy,,,,AEWS 1031,,,,,,,
92,Optic Nerve,Conventional,General,Meningioma,0.03 cc,,,50 Gy,55 Gy,,,RTOG 0539,,,,,,,Optic neuropathy rates for 55 / 60 / 60+ Gy Dmax of 3→ 7→ 7-20%.
1172,Optic Nerve,Conventional,General,Pediatrics,100%,,,54 Gy,,,,AEWS 1031,,,,,,,
93,Cochlea,1,General,,Max,,,9 Gy,,,,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101,QUANTEC",,Mendenhall JNS '96,https://thejns.org/view/journals/j-neurosurg/85/6/article-p1013.xml,Combs IJROBP '10,https://www.redjournal.org/article/S0360-3016(09)00208-9/fulltext,14 Gy with < 25% incidence of SNHL (similar to 45/25). Limit prescription dose to 12-14 Gy to preserve hearing.
94,Cochlea,5,General,,Max,,,25 Gy,,,,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,
95,Cochlea,3,General,,Max,,,17.1 Gy,,,,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,
96,Cochlea,1,General,,Mean,,,4 Gy,,,,,,,,,,,
97,Cochlea,10,General,,Max,,,32.2 Gy,,,,,,,,,,,
98,Cochlea,Conventional,General,,5%,,,55 Gy,60 Gy,,,,DAHANCA,Should,,,,,
99,Cochlea,Conventional,General,,Mean,,,45 Gy,50 Gy,,,,DAHANCA,Should,,,,,
100,Cochlea,Conventional,General,,Max,,,45 Gy,55 Gy,,,,QUANTEC,,,,,,Risk of SNHL for mean cochlear dose of 45 Gy < 30% (similar to 14/1). 
101,Cochlea,5,Re-irradiation,,Mean,,,15 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
102,Cochlea,Conventional,General,Pediatrics,Mean,,,35 Gy,,,,,,,Yock ASTRO '19,https://www.eventscribe.com/2019/ASTRO/fsPopup.asp?Mode=presInfo&PresentationID=559439,,,Risk of SNHL for mean cochlear dose of 45 Gy < 30% (similar to 14/1). 
103,Cochlea,Conventional,General,Pediatrics,50%,,,30 Gy,,,,,,,Yock ASTRO '19,https://www.eventscribe.com/2019/ASTRO/fsPopup.asp?Mode=presInfo&PresentationID=559439,,,Risk of SNHL for mean cochlear dose of 45 Gy < 30% (similar to 14/1). 
1141,Cochlea,Conventional,General,Pediatrics,Min,,,20 Gy,,,,,,,Cohen-Cutler IJROBP '21,https://pubmed.ncbi.nlm.nih.gov/33677052/,,,Risk of SNHL for mean cochlear dose of 45 Gy < 30% (similar to 14/1). 
1175,Cochlea,Conventional,General,Pediatrics,100%,,,40 Gy,,,,AEWS 1031,,,,,,,
104,Pituitary,Conventional,General,,Max,,,45 Gy,,,,,,,Needs source,,,,"Hypopituitarism TD 5/5 40-45 Gy. GH decreases first, then LH/FSH followed by TSH/ACTH. "
105,Pituitary,1,General,,Max,,,13 Gy,19 Gy,,,,,,Needs source,,,,
106,Pituitary,5,General,,40%,,,7.3 Gy,,,,,,,,,,,
107,Pituitary,Conventional,General,,Mean,,,40 Gy,,,,,,,,,,,
108,Pituitary,Conventional,General,,Mean,,,20 Gy,,,,,DAHANCA,Should,,,,,
109,Pituitary,Conventional,General,,Mean,,,20 Gy,,,,,DAHANCA,Should,,,,,
110,Pituitary,Conventional,General,Pediatrics,Mean,,,18 Gy,,,,,,,,,,,
111,Hippocampus,Conventional,General,,Max,,,16 Gy,17 Gy,,,"NRG CC001,RTOG 0933",,,,,,,
112,Hippocampus,Conventional,General,,Max,,,14 Gy,,,,,,,Redmond ASTRO '20,https://www.redjournal.org/article/S0360-3016(20)32375-0/fulltext,,,
113,Hippocampus,Conventional,General,,D100,,,9 Gy,10 Gy,,,"NRG CC001,RTOG 0933",,,,,,,10 Gy leads to neural stem cell reduction
114,Hippocampus,Conventional,General,,D40,,,7.2 Gy,,EQD2,,,DAHANCA,Can,Gondi IJROBP '13,https://pubmed.ncbi.nlm.nih.gov/22209148/,,,Risk for poor memory for D40% ± 7.2 Gy of 11→ 66% 
115,Circle_of_Willis,Conventional,General,Pediatrics,Max,,,10 Gy,,,,,,,El-Fayech IJROBP '17,https://www.ncbi.nlm.nih.gov/pubmed/28068236,,,
116,Lens,Conventional,General,,Max,,,6 Gy,15 Gy,,,,,,,,,,"After 2.5-6.5 Gy, 33% develop cataracts after 8y latent period. After 6.5-11.5 Gy, 66% develop cataracts after 4y latent period. Lens opacification at > 13-16 Gy."
117,Lens,1,General,,0.1 cc,,,1.5 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
118,Lens,3,General,,ALARA,,,,,,,,,,,,,,
119,Lens,5,Re-irradiation,,Max,,,5 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
120,Lens,Conventional,General,,Max,,,7 Gy,,,,RTOG 0825,,,,,,,"After 2.5-6.5 Gy, 33% develop cataracts after 8y latent period. After 6.5-11.5 Gy, 66% develop cataracts after 4y latent period. Lens opacification at > 13-16 Gy."
121,Lens,15-16,General,,Max,,,4 Gy,,,,,,,Perry NEJM '17,https://pubmed.ncbi.nlm.nih.gov/28296618/,,,
122,Lens,Conventional,General,Meningioma,0.03 cc,,,5 Gy,7 Gy,,,RTOG 0539,,,,,,,"After 2.5-6.5 Gy, 33% develop cataracts after 8y latent period. After 6.5-11.5 Gy, 66% develop cataracts after 4y latent period. Lens opacification at > 13-16 Gy."
123,Lens,Conventional,General,Nasopharynx,Max,,,25 Gy,,,,RTOG 0615,,,,,,,"After 2.5-6.5 Gy, 33% develop cataracts after 8y latent period. After 6.5-11.5 Gy, 66% develop cataracts after 4y latent period. Lens opacification at > 13-16 Gy."
124,Lens,Conventional,General,Pediatrics,Max,,,14.4 Gy,,,,ARST 1431,,,,,,,"After 2.5-6.5 Gy, 33% develop cataracts after 8y latent period. After 6.5-11.5 Gy, 66% develop cataracts after 4y latent period. Lens opacification at > 13-16 Gy."
1174,Lens,Conventional,General,Pediatrics,100%,,,6 Gy,,,,AEWS 1031,,,,,,,
125,Orbit,Conventional,General,,Max,,,55 Gy,,,,,,,,,,,
126,Orbit,Conventional,General,,Mean,,,35 Gy,,,,,,,,,,,
127,Orbit,5,General,,Max,,,32 Gy,,,,"BR002,RTOG 0813,SUNSET",,,,,,,
128,Orbit,3,General,,Max,,,26 Gy,,,,BR002,"Timmerman,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
129,Orbit,1,General,,0.1 cc,,,8 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
130,Orbit,3,General,,Max,,,24 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
131,Orbit,3,General,,3 cc,,,20.4 Gy,22 Gy,,,BR002,"TG-101,Timmerman",,,,,,
132,Orbit,3,General,,0.5 cc,,,24 Gy,26 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
133,Orbit,5,General,,0.5 cc,,,27 Gy,29 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
134,Orbit,5,General,,3 cc,,,27 Gy,30 Gy,,,"BR002,RTOG 0813",TG-101,,,,,,
135,Orbit,5,General,,Max,,,30.5 Gy,,,,,"TG-101,Timmerman",,,,,,
136,Orbit,Conventional,General,Pediatrics,Mean,,,30 Gy,,,,,,,Tinkle IJROBP ‘20,https://www.ncbi.nlm.nih.gov/pubmed/31987969,,,Orbital hypoplasia with mean bony dose >= 30 Gy.
1173,Orbit,Conventional,General,Pediatrics,100%,,,45 Gy,,,,AEWS 1031,,,,,,,
137,EyeBack (Retina),Conventional,General,,0.03 cc,,,45 Gy,,,,,DAHANCA,Must,,,,,5y retinopathy for < 24 / 45-50 / 55 / 70-80 Gy of 0→ 5→ 50→ 85%. There is a sharp increase above 50 Gy.
138,EyeBack (Retina),3,General,,Max,,,25.5 Gy,,,,BR002,Timmerman,,,,,,
139,EyeBack (Retina),3,General,,Max,,,24 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
140,EyeBack (Retina),3,General,,5 cc,,,21.9 Gy,,,,BR002,"TG-101,Timmerman",,,,,,
141,EyeBack (Retina),3,General,,0.5 cc,,,24 Gy,26 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
142,EyeBack (Retina),5,Re-irradiation,,Mean,,,15 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
143,EyeBack (Retina),5,General,,Max,,,32 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
144,EyeBack (Retina),5,General,,5 cc,,,30 Gy,,,,BR002,TG-101,,,,,,
145,EyeBack (Retina),Conventional,General,,0.03 cc,,0.3 cm,50 Gy,,,,,DAHANCA,Must,,,,,5y retinopathy for < 24 / 45-50 / 55 / 70-80 Gy of 0→ 5→ 50→ 85%. There is a sharp increase above 50 Gy.
146,EyeBack (Retina),Conventional,General,,0.03 cc,,,45 Gy,50 Gy,,,RTOG 0539,,,,,,,5y retinopathy for < 24 / 45-50 / 55 / 70-80 Gy of 0→ 5→ 50→ 85%. There is a sharp increase above 50 Gy.
147,EyeFront,Conventional,General,,Max,,,30 Gy,,,,,DAHANCA,Must,,,,,"Eyelash: Loss at >20 Gy conventional fractionation (20/10 for Graves). Chronic skin/eyelid changes > 50 Gy. Conjunctivitis: Acute > 30 Gy, chronic >50 Gy, permanent conjunctival scarring > 60 Gy. Corneal ulceration: > 60 Gy, late conjunctival scarring > 50 Gy."
148,EyeFront,Conventional,General,,Max,,0.3 cm,35 Gy,,,,,DAHANCA,Must,,,,,"Eyelash: Loss at >20 Gy conventional fractionation (20/10 for Graves). Chronic skin/eyelid changes > 50 Gy. Conjunctivitis: Acute > 30 Gy, chronic >50 Gy, permanent conjunctival scarring > 60 Gy. Corneal ulceration: > 60 Gy, late conjunctival scarring > 50 Gy."
149,Brachial_Plexus,Conventional,General,,Mean,,,69 Gy,,,,,,,,,,,
150,Brachial_Plexus,Conventional,General,,0.1 cc,0.5 cc,,75 Gy,,,,RTOG 1308,,,,,,,
151,Brachial_Plexus,Conventional,General,,0.5 cc,1.0 cc,,74 Gy,,,,RTOG 1308,,,,,,,
152,Brachial_Plexus,Conventional,General,,1.0 cc,1.5 cc,,70 Gy,,,,RTOG 1308,,,,,,,
153,Brachial_Plexus,Conventional,General,,2.0 cc,2.5 cc,,66 Gy,,,,RTOG 1308,,,,,,,
154,Brachial_Plexus,1,General,,Max,,,17.5 Gy,,,,"RTOG 0915,BR002,RTOG 0631","Timmerman,TG-101",,,,,,
155,Brachial_Plexus,1,General,,3 cc,,,14 Gy,,,,"RTOG 0915,BR002,RTOG 0631","Timmerman,TG-101",,,,,,
156,Brachial_Plexus,3,General,,Max,,,26 Gy,,,,BR002,"Timmerman,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
157,Brachial_Plexus,3,General,,Max,,,24 Gy,,,,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,
158,Brachial_Plexus,3,General,,3 cc,,,20.4 Gy,22 Gy,,,BR002,"TG-101,Timmerman",,,,,,
159,Brachial_Plexus,3,General,,0.5 cc,,,24 Gy,26 Gy,,,RTOG 0618,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,
160,Brachial_Plexus,5,General,,0.5 cc,,,27 Gy,29 Gy,,,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,
161,Brachial_Plexus,5,General,,3 cc,,,27 Gy,30 Gy,,,"BR002,RTOG 0813",TG-101,,,,,,
162,Brachial_Plexus,5,General,,Max,,,30.5 Gy,,,,,"TG-101,Timmerman",,,,,,
163,Brachial_Plexus,5,General,,Max,,,32 Gy,,,,"BR002,RTOG 0813,SUNSET",,,,,,,
164,Brachial_Plexus,5,General,,Max,,,35 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
165,Brachial_Plexus,8,General,NSCLC,0.5 cc,,,38 Gy,41.36 Gy,,,LungTECH,,,,,,,
166,Brachial_Plexus,8,General,,Max,,,39 Gy,,,,SUNSET,,,,,,,
167,Brachial_Plexus,8,General,,0.5 cc,,,27 Gy,38 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
168,Brachial_Plexus,10,General,,Max,,,55 Gy,,Extrapolation,,RTOG 0813,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
169,Brachial_Plexus,10,General,,0.2 cc,,,50 Gy,,,,,,,,,,,
170,Brachial_Plexus,10,General,,Max,,,39 Gy,,,,SUNSET,,,,,,,
171,Brachial_Plexus,10,General,,3 cc,,,34.9 Gy,,,,,,,,,,,
172,Brachial_Plexus,15-16,General,,Max,,,50 Gy,,,,SUNSET,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
173,Brachial_Plexus,15-16,General,,Max,,,49.8 Gy,52 Gy,,,NRG LU004,,,,,,,
174,Brachial_Plexus,Conventional,General,,Max,,,66 Gy,,,,RTOG 0617,,,,,,,
175,Cauda_Equina,Conventional,General,,,,,66 Gy,70 Gy,,,,,,,,,,
176,Cauda_Equina,1,General,,Max,,,16 Gy,,,,"RTOG 0631,BR002","Timmerman,TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
177,Cauda_Equina,1,General,,5 cc,,,14 Gy,,,,"RTOG 0631,BR002","Timmerman,TG-101",,,,,,
178,Cauda_Equina,3,General,,5 cc,,,21.9 Gy,,,,BR002,TG-101,,,,,,
179,Cauda_Equina,3,General,,Max,,,25.5 Gy,,,,BR002,Timmerman,,,,,,
180,Cauda_Equina,3,General,,Max,,,24 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
181,Cauda_Equina,5,General,,5 cc,,,30 Gy,,,,BR002,TG-101,,,,,,
182,Cauda_Equina,5,General,,Max,,,32 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
183,Cauda_Equina,10,General,,Max,,,41.9 Gy,,,,,,,,,,,
184,Cauda_Equina,10,General,,5 cc,,,39.1 Gy,,,,,,,,,,,
185,Sacral_Plexus,Conventional,General,,Max,,,66 Gy,70 Gy,,,,,,,,,,
186,Sacral_Plexus,3,General,,Max,,,24 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
187,Sacral_Plexus,3,General,,5 cc,,,22.5 Gy,,,,BR002,TG-101,,,,,,
188,Sacral_Plexus,5,General,,5 cc,,,30 Gy,,,,BR002,TG-101,,,,,,
189,Sacral_Plexus,5,General,,Max,,,32 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
190,Sacral_Plexus,10,General,,5 cc,,,39.1 Gy,,,,,,,,,,,
191,Sacral_Plexus,10,General,,Max,,,41.9 Gy,,,,,,,,,,,
192,Sacral_Plexus,1,General,,5 cc,,,14.4 Gy,,,,"RTOG 0631,BR002","Timmerman,TG-101",,,,,,
193,Sacral_Plexus,1,General,,Max,,,16 Gy,18 Gy,,,"RTOG 0631,BR002","TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
194,Sacral_Plexus,2,General,,Max,,,26 Gy,,,,SC.24,,,,,,,
195,Skin,Conventional,General,,Max,,,20 Gy,30 Gy,,,,,,,,,,
196,Skin,1,General,,Max,,,26 Gy,27.5 Gy,,,"BR002,RTOG 0631","Timmerman,TG-101",,,,,,
197,Skin,1,General,,10 cc,,,23 Gy,25.5 Gy,,,"BR002,RTOG 0631","Timmerman,TG-101",,,,,,
198,Skin,3,General,,10 cc,,,30 Gy,31 Gy,,,BR002,"Timmerman,TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
199,Skin,3,General,,Max,,,33 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
200,Skin,5,General,,Max,,,38.5 Gy,39.5 Gy,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,Timmerman",,,,,,
201,Skin,5,Re-irradiation,,10 cc,,,39.5 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
202,Skin,5,General,,10 cc,,,36.5 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,Timmerman",,,,,,
203,Skin,5,General,,10 cc,,,30 Gy,,,,RTOG 0813,,,,,,,
204,Skin,5,General,,Max,,,32 Gy,,,,RTOG 0813,,,,,,,
205,Skin,10,General,,Max,,,82 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
206,Skin,10,General,,Max,,,52.3 Gy,,,,,,,Needs source,,,,
207,Skin,10,General,,60 cc,,,50 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
208,Skin,10,General,,10 cc,,,48.1 Gy,,,,,,,Needs source,,,,
209,Skin,10,General,,120 cc,,,40 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
210,Skin,10,General,,250 cc,,,30 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
211,Skin,Conventional,General,Sarcoma,50%,,,20 Gy,,,,RTOG 0631,,,,,,,Spare 1 cm strip
212,Carotid Artery,Conventional,Re-irradiation,,Max,,,120 Gy,,EQD2,,,,,,,,,
213,Carotid Artery,Conventional,General,,Max,,,40 Gy,,,,,DAHANCA,Can,,,,,
214,Carotid Artery,5,Re-irradiation,,Max,,,32.5 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
215,Temporal Lobe,Conventional,General,,Max,,,65 Gy,72 Gy,,,,,,Lee IJROBP '19,https://www.redjournal.org/article/S0360-3016(19)33428-5/pdf,,,Early stage NPC
216,Temporal Lobe,Conventional,General,,Max,,,70 Gy,72 Gy,,,,,,Lee IJROBP '19,https://www.redjournal.org/article/S0360-3016(19)33428-5/pdf,,,Late stage NPC
217,Temporal Lobe,5,Re-irradiation,,Mean,,,5 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
218,Lips,Conventional,General,,Mean,,,20 Gy,,,,RTOG 1016,DAHANCA,Can,,,,,
219,Lips,Conventional,General,,Max,,,35 Gy,50 Gy,,,,,,Needs source,,,,50 Gy if oral cavity
220,BuccalMuc,Conventional,General,,Mean,,,30 Gy,,,,,DAHANCA,Can,,,,,
221,Oral_Cavity,Conventional,General,,Mean,,,40 Gy,50 Gy,,,,,,Little IJROBP '12,https://www.ncbi.nlm.nih.gov/pubmed/22056067,Narayan IJROBP '08,https://www.ncbi.nlm.nih.gov/pubmed/18417299,Oral cavity mean dose < 40 Gy is associated with low patient reported xerostomia 
222,Oral_Cavity,Conventional,General,,Mean,,,30 Gy,60 Gy,,,RTOG 1016,DAHANCA,Should,,,,,Uninvolved
223,Oral_Cavity,Conventional,General,H&N: Oral Cavity,Mean,,,55 Gy,65 Gy,,,,,,Sapir IJROBP '16,https://www.ncbi.nlm.nih.gov/pubmed/27473816,,,Mean oral cavity dose of 53 Gy is associated with severe dysgeusia at 3 months 
224,Gland_Lacrimal,Conventional,General,,Mean,,,25 Gy,,,,,DAHANCA,Must,,,,,
225,Gland_Lacrimal,Conventional,General,,Max,,,60 Gy,,,,,,,Bhandare IJROBP '21,https://www.sciencedirect.com/science/article/pii/S0360301611007498,,,Severe DES with visual compromise for 35-40 / 45-50 / 60-65 Gy of 6→ 50→ 90%. Latency to DES for 35 / 40 / 50+ Gy mean of 30→ 20→ 10 mo. Freedom from severe DES for < 45 / 45-59.9 / ≥ 60 Gy mean of 93→ 29→ 3%.
226,Gland_Lacrimal,Conventional,General,,TD 5/5,,,35 Gy,,,,,,,,,,,"TD 5/5 35 Gy. TD 50/5 50 Gy, permanent > 60 Gy mean. There is a sharp increase above 50 Gy."
227,Gland_Lacrimal,Conventional,General,,Mean,,0.3 cm,30 Gy,,,,,DAHANCA,Must,,,,,
228,Gland_Lacrimal,Conventional,General,Pediatrics,Mean,,,30 Gy,41.4 Gy,,,ARST 1431,,,,,,,
229,Parotid_Ipsi,Conventional,General,,Mean,,,26 Gy,33 Gy,,,RTOG 1016,,,,,,,
230,Parotid_Ipsi,Conventional,General,,50%,,,30 Gy,,,,,,,,,,,1 gland V30 < 50%
231,Parotid_Contra,Conventional,General,,Mean,,,20 Gy,24 Gy,,,,"DAHANCA,QUANTEC",Should,PARSPORT Nutting Lanc Onc '11,https://www.sciencedirect.com/science/article/pii/S1470204510702904?via%3Dihub,,,Mean unilateral parotid dose of 20 Gy with < 20% risk of parotid gland function < 25% of pre-RT level
232,Parotid_Contra,Conventional,General,,50%,,,30 Gy,,,,,,,,,,,1 gland V30 < 50%
233,Parotid_Contra,Conventional,General,,33%,,,40 Gy,,,,,,,,,,,If unilateral
234,Parotids,Conventional,General,,Mean,,,24 Gy,26 Gy,,,,"DAHANCA,QUANTEC",Should,Dijkema IJROBP '10,https://www.ncbi.nlm.nih.gov/pubmed/20056347,,,Mean bilateral parotid dose of 25 / 39 Gy with < 20→ 50% risk of reduced parotid gland function to < 25% of pre-RT level
235,Parotids,Conventional,General,,20 cc,,,20 Gy,,,,,,,,,,,
236,Parotids,2,General,,Mean,,,5 Gy,,,,SC.24,,,,,,,
237,Submandibular,Conventional,General,,Mean,,,30 Gy,35 Gy,,,,"DAHANCA,QUANTEC",Should,,,,,Complete loss of salivary gland function is possible after 35-39 Gy.
238,Submandibular_Contra,Conventional,General,,Mean,,,39 Gy,,,,RTOG 1016,QUANTEC,,Murdoch-Kinch IJROBP '08,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734803/,,,Complete loss of salivary gland function is possible after 35-39 Gy.
239,Thyroid,Conventional,General,,Max,,,45 Gy,,,,,,,,,,,
240,Thyroid,Conventional,General,,Mean,,,37 Gy,40 Gy,,,,DAHANCA,Should,Kamal ARO '19,https://www.ncbi.nlm.nih.gov/pubmed/32051897,,,
241,Thyroid,5,Re-irradiation,,Max,,,30 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
242,Thyroid,Conventional,General,,25%,,,50 Gy,,,,,,,Zhou Rad Onc '20,https://www.ncbi.nlm.nih.gov/pubmed/32293496,,,Thyroid V50 ± 25% with hypothyroidism of 34→ 55%
243,Thyroid,Conventional,General,Pediatrics,62.5%,,,25 Gy,,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,,,Thyroid abnormalities are more common > 26 Gy
244,Thyroid,Conventional,General,Pediatrics,93%,,,5 Gy,,,,,,,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,,,
245,Thyroid,Conventional,General,Pediatrics,82%,,,20 Gy,,,,,,,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,,,
246,Thyroid,Conventional,General,Pediatrics,63%,70%,,25 Gy,,,,,,,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,,,Thyroid abnormalities are more common > 26 Gy
247,Thyroid,Conventional,General,Pediatrics,62%,,,30 Gy,,,,,,,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,,,Thyroid abnormalities are more common > 26 Gy
248,Thyroid,Conventional,General,Pediatrics,2.2 cc,,,25 Gy,,,,,,,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,,,Thyroid abnormalities are more common > 26 Gy
249,Thyroid,Conventional,General,Pediatrics,20%,,,26 Gy,,,,,,,Needs source,,,,Thyroid > 15 Gy is associated with a 30% risk of thyroid insufficiency
250,Thyroid,Conventional,General,Pediatrics,Max,,,30.6 Gy,,,,,,,Needs source,,,,Thyroid > 15 Gy is associated with a 30% risk of thyroid insufficiency
251,Pterygoid_Lat,Conventional,General,,Mean,,,61 Gy,,,,,,,Kamal RTO '20,https://www.ncbi.nlm.nih.gov/pubmed/32387489,,,
252,Pterygoid_Lat,Conventional,General,,98.6%,,,27 Gy,,,,,,,Kamal RTO '20,https://www.ncbi.nlm.nih.gov/pubmed/32387489,,,
253,Constrictor_L,Conventional,General,,Mean,,,30 Gy,55 Gy,,,,DAHANCA,Should,Eisbruch IJROBP '11,https://www.ncbi.nlm.nih.gov/pubmed/21592678,,,"Sup constrictor < 50 Gy most important, or for OP/NPX, limit the larynx and inf constrictors to ≤ 20-30 Gy"
254,Constrictor_M,Conventional,General,,Mean,,,,55 Gy,,,,DAHANCA,Should,,,,,
255,Constrictor_S,Conventional,General,,Mean,,,50 Gy,55 Gy,,,,DAHANCA,Should,Eisbruch IJROBP '11,https://www.ncbi.nlm.nih.gov/pubmed/21592678,,,"Sup constrictor < 50 Gy most important, or for OP/NPX, limit the larynx and inf constrictors to ≤ 20-30 Gy"
256,Constrictors,Conventional,General,,Mean,,,50 Gy,,,,,QUANTEC,,,,,,Mean < 50 Gy with ~20% symptomatic dysphagia and aspiration. 
1142,Constrictors,Conventional,General,,Mean,,,50 Gy,,,,,QUANTEC,,DARS Nutting ASCO '20,https://pubmed.ncbi.nlm.nih.gov/27716125/,"The superior and middle constrictors will be contoured as one structure, while IPCM as a separate structure. The S/MPC or IPC lying outside high-dose CTV was set a mandatory mean dose constraint < 50 Gy.",,Mean < 50 Gy with ~20% symptomatic dysphagia and aspiration. 
257,Larynx,Conventional,General,,Max,,,63 Gy,66 Gy,,,,QUANTEC,,,,,,70 Gy to larynx carries 5% risk of cartilage necrosis. 66 Gy to larynx carries < 20% risk of vocal dysfunction with chemotherapy. 
258,Larynx,Conventional,General,,Mean,,,45 Gy,,,,RTOG 1016,QUANTEC,,Sanguineti IJROBP '07,https://www.redjournal.org/article/S0360-3016(07)00113-7/fulltext,,,Risk of aspiration with mean laryngeal dose 50 Gy < 30%. Mean laryngeal dose of 44 Gy (RT alone) with < 20% edema. Keep MLD < 43.5 Gy to minimize risk of G2+ edema.
259,Larynx,Conventional,General,,15%,,,60 Gy,,,,RTOG 1016,QUANTEC,,,,,,
260,Larynx,Conventional,General,,33%,,,50 Gy,,,,RTOG 1016,QUANTEC,,,,,,V50 < 27% with < 20% edema.
261,Larynx,Conventional,General,,66%,,,50 Gy,,,,,QUANTEC,,,,,,V50 < 27% with < 20% edema.
262,Larynx,5,Re-irradiation,,Mean,,,15 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
263,Larynx,1,General,,Max,,,20.2 Gy,,,,RTOG 0631,,,,,,,
264,Larynx,1,General,,4 cc,,,10.5 Gy,,,,RTOG 0631,,,,,,,
265,Larynx,2,General,,Max,,,20 Gy,,,,SC.24,,,,,,,
266,Larynx,2,General,,Mean,,,8 Gy,,,,SC.24,,,,,,,
267,Larynx,Conventional,General,Pediatrics,Mean,,,19.8 Gy,,,,,,,,,,,Block at 19.8 Gy when necessary for HL
268,Larynx_Glottic,Conventional,General,,Mean,,,35 Gy,40 Gy,,,,"QUANTEC,DAHANCA",Should,,,,,
269,Larynx_Glottic,Conventional,General,,D2%,,,50 Gy,,,,,QUANTEC,,,,,,
270,Larynx_Glottic,Conventional,General,,Mean,,,20 Gy,,,,RTOG 1016,,,,,,,
271,Larynx_SGL,Conventional,General,,Mean,,,40 Gy,,,,,"QUANTEC,DAHANCA",Should,,,,,
272,Pharynx_post_wall,Conventional,General,,33%,,,50 Gy,,,,RTOG 1016,,,,,,,
273,Pharynx_post_wall,Conventional,General,,15%,,,60 Gy,,,,RTOG 1016,,,,,,,
274,Pharynx_post_wall,Conventional,General,,Mean,,,45 Gy,,,,RTOG 1016,,,,,,,
275,Pharynx_post_wall,2,General,,Max,,,20 Gy,,,,SC.24,,,,,,,
276,Pharynx_post_wall,2,General,,Mean,,,8 Gy,,,,SC.24,,,,,,,
277,Mandible,Conventional,General,,1%,2%,,70 Gy,75 Gy,,,RTOG 0225,,,,,,,
278,Mandible,Conventional,General,,Max,,,66 Gy,,,,RTOG 1016,,,,,,,
279,Mandible,Conventional,General,,14%,,,60 Gy,,,,,,,Kubota Rad Onc '21,https://pubmed.ncbi.nlm.nih.gov/33402192/,,,3y cumulative ORN for V60 ± 14% of 3→ 9% 
280,Mandible,Conventional,General,,Max,,,72 Gy,,,,,DAHANCA,Should,,,,,
281,Mandible,5,Re-irradiation,,Max,,,20 Gy,,,,,,,Iqbal BJR '20,https://pubmed.ncbi.nlm.nih.gov/32960652/,,,
282,Mandible,Conventional,General,,42%,,,44 Gy,,,,,,,MDACC RTO '17,https://pubmed.ncbi.nlm.nih.gov/28733053/,,,
283,Mandible,Conventional,General,,25%,,,52 Gy,,,,,,,MDACC RTO '17,https://pubmed.ncbi.nlm.nih.gov/28733053/,,,
284,Mandible,Conventional,General,Nasopharynx,1 cc,,,75 Gy,,,,RTOG 0615,,,,,,,
285,Esophagus_Cervical,Conventional,General,,Mean,,,30 Gy,,,,RTOG 1016,DAHANCA,Should,,,,,
286,Esophagus_Cervical,Conventional,General,,Max,,,50 Gy,,,,,,,,,,,
287,Esophagus,Conventional,General,,1 cc,1.5 cc,,74 Gy,,,,RTOG 1308,QUANTEC,,,,,,Point doses of 74 Gy appear to be safe even with concurrent carboplatin and paclitaxel. 
288,Esophagus,Conventional,General,NSCLC,Mean,,,34 Gy,37 Gy,,,RTOG 0617,QUANTEC,,,,,,MED < 34 Gy is not mandated on RTOG 06-17! G3+ acute esophagitis is 5-20% with MED < 34 Gy. 
289,Esophagus,Conventional,General,,17%,,,60 Gy,,,,,,,Needs source,,,,
290,Esophagus,Conventional,General,,7%,,,60 Gy,,,,,,,Voong PRO '20,https://pubmed.ncbi.nlm.nih.gov/33137465/,,,
291,Esophagus,Conventional,General,,33%,,,55 Gy,,,,,,,Needs source,,,,
292,Esophagus,1,General,,Max,,,15.4 Gy,,,,"RTOG 0631,BR002","TG-101,Timmerman",,,,,,
293,Esophagus,1,General,,5 cc,,,11.9 Gy,,,,"RTOG 0631,RTOG 0915,BR002",,,,,,,
294,Esophagus,3,General,,Max,,,27 Gy,,,,"RTOG 0618,BR002",Timmerman,,,,,,
295,Esophagus,3,General,,5 cc,,,17.7 Gy,,,,BR002,TG-101,,,,,,
296,Esophagus,3,General,,Max,,,25.2 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
297,Esophagus,5,General,NSCLC,0.05 cc,,,52.5 Gy,63 Gy,,,RTOG 0813,,,,,,,
298,Esophagus,5,General,,Max,,,40 Gy,,,,SUNSET,,,,,,,
299,Esophagus,5,General,,5 cc,,,35 Gy,,,,SUNSET,,,,,,,
300,Esophagus,5,General,,0.5 cc,,,32 Gy,34 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
301,Esophagus,5,General,,5 cc,,,19.5 Gy,27.5 Gy,,,"BR002,RTOG 0813",TG-101,,,,,,
302,Esophagus,5,General,,Max,,,35 Gy,,,,BR002,"Timmerman,TG-101",,,,,,
303,Esophagus,8,General,,Max,,,63 Gy,,Extrapolation,,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
304,Esophagus,8,General,,0.5 cc,,,40 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
305,Esophagus,8,General,,Max,,,40 Gy,43.52 Gy,,,LungTECH,,,,,,,
306,Esophagus,8,General,,5 cc,,,32.8 Gy,,Extrapolation,,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
307,Esophagus,8,General,,5 cc,,,40 Gy,,,,SUNSET,,,,,,,
308,Esophagus,8,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
309,Esophagus,10,General,,Max,,,50 Gy,,Extrapolation,,RTOG 0813,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
310,Esophagus,10,General,,5 cc,,,24.6 Gy,,,,,,,Needs source,,,,
311,Esophagus,10,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
312,Esophagus,10,General,,1 cc,,,40 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
313,Esophagus,10,General,,5 cc,,,40 Gy,,,,SUNSET,,,,,,,
314,Esophagus,Conventional,General,,20%,,,70 Gy,,,,,QUANTEC,,,,,,G2+ esophagitis < 30%
315,Esophagus,Conventional,General,,40%,,,50 Gy,,,,,QUANTEC,,,,,,G2+ esophagitis < 30%
316,Esophagus,Conventional,General,,50%,,,35 Gy,,,,,QUANTEC,,,,,,G2+ esophagitis < 30%
317,Esophagus,Conventional,General,,Partial Circumference,Full Circumference,,50 Gy,60 Gy,,,,,,Han PRO '20,https://www.practicalradonc.org/article/S1879-8500(20)30062-X/fulltext,,,The length of partial and near-full circumference esophagus receiving 50-60 Gy appears to contribute to weight loss
318,Esophagus,15-16,General,,Max,,,58.9 Gy,61.3 Gy,,,NRG LU004,,,,,,,
319,Esophagus,15-16,General,,Circumference: Full,,,53.1 Gy,,,,NRG LU004,,,,,,,
320,Esophagus,15-16,General,,Max,,,50.5 Gy,,,,SUNSET,,,,,,,
321,Esophagus,15-16,General,,5 cc,,,48 Gy,,,,SUNSET,,,,,,,
322,Esophagus,15-16,General,,4 cc,,,50 Gy,,,,,,,Kong IJROBP '20,https://doi.org/10.1016/j.ijrobp.2020.03.038,,,
323,Esophagus,15-16,General,,Max,,,40 Gy,50 Gy,,,,,,NCIC CTV BR.25,https://academic.oup.com/jnci/article/106/8/dju164/910382,,,
324,Esophagus,15-16,General,,Mean,,,31 Gy,32 Gy,,,NRG LU004,,,NCIC CTV BR.25,https://academic.oup.com/jnci/article/106/8/dju164/910382,,,
325,Esophagus,2,General,,Max,,,20 Gy,,,,SC.24,,,,,,,
1160,Esophagus,Conventional,General,Pediatrics,50%,,,40 Gy,,,,AEWS 1031,,,,,,,
326,Heart,Conventional,General,,Mean,,,26 Gy,35 Gy,,,QUANTEC,,,Wang JTO '20,https://www.sciencedirect.com/science/article/abs/pii/S1556086420304998,,,2y cardiac events for Mean Heart Dose < 10 / 10-20 / >20 Gy of 4→ 7→ 21%. Mean heart dose < 26 Gy is associated with < 15% pericarditis.
327,Heart,Conventional,General,Esophageal,Mean,,,15 Gy,20 Gy,,,,,,Wang JTO '20,https://www.sciencedirect.com/science/article/abs/pii/S1556086420304998,,,2y cardiac events for Mean Heart Dose < 10 / 10-20 / >20 Gy of 4→ 7→ 21%
328,Heart,Conventional,General,,Max,,,70 Gy,,,,,,,Needs source,,,,
329,Heart,Conventional,General,NSCLC,33%,,,60 Gy,,,,RTOG 0617,,,,,,,
330,Heart,Conventional,General,NSCLC,67%,,,45 Gy,,,,RTOG 0617,,,,,,,
331,Heart,Conventional,General,NSCLC,80%,100%,,40 Gy,,,,RTOG 0617,,,,,,,
332,Heart,Conventional,General,NSCLC,25%,33%,,50 Gy,,,,RTOG 0617,,,Speirs JTO '16,https://www.jto.org/article/S1556-0864(16)31144-3/fulltext,,,V50 < 25% is independently associated with overall survival 
333,Heart,Conventional,General,Esophageal,35%,,,45 Gy,,,,RTOG 1308,,,,,,,
334,Heart,1,General,,Max,,,22 Gy,,,,RTOG 0631,"TG-101,Timmerman",,,,,,
335,Heart,1,General,,15 cc,,,16 Gy,,,,RTOG 0631,"TG-101,Timmerman",,,,,,
336,Heart,3,General,,Max,,,36 Gy,,,,,,,Needs source,,,,
337,Heart,3,General,,Max,,,30 Gy,,,,BR002,TG-101,,,,,,
338,Heart,3,General,,0.5 cc,,,24 Gy,26 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
339,Heart,3,General,,15 cc,,,24 Gy,,,,BR002,TG-101,,,,,,
340,Heart,5,General,NSCLC,Max,,,62 Gy,,,,SUNSET,,,,,,,
341,Heart,5,General,NSCLC,0.05 cc,,,52.5 Gy,63 Gy,,,RTOG 0813,,,,,,,"105% Rx (e.g., 50-60/5)"
342,Heart,5,General,NSCLC,10 cc,,,50 Gy,,,,SUNSET,,,,,,,
343,Heart,5,General,,Max,,,38 Gy,,,,BR002,"TG-101,Timmerman",,,,,,
344,Heart,5,General,Pancreas,Max,,,30 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
345,Heart,5,General,,15 cc,,,32 Gy,,,,"BR002,RTOG 0813",TG-101,,,,,,
346,Heart,5,General,,0.5 cc,,,27 Gy,29 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
347,Heart,8,General,,Max,,,64 Gy,,Extrapolation,,"SUNSET,RTOG 0813",,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
348,Heart,8,General,,0.5 cc,,,50 Gy,60 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
349,Heart,8,General,,10 cc,,,60 Gy,,,,SUNSET,,,,,,,
350,Heart,8,General,,Max,,,44 Gy,,,,,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
351,Heart,8,General,,15 cc,,,38.4 Gy,,,,,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
352,Heart,10,General,,Max,,,64 Gy,,,,SUNSET,,,,,,,
353,Heart,10,General,,Max,,,60 Gy,,Extrapolation,,RTOG 0813,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
354,Heart,10,General,,10 cc,,,60 Gy,,,,SUNSET,,,,,,,
355,Heart,10,General,,1 cc,,,45 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
356,Heart,10,General,,15 cc,,,41.9 Gy,,,,,,,Needs source,,,,
357,Heart,Conventional,General,Esophageal,50%,,,40 Gy,45 Gy,,,RTOG 1010,,,,,,,
358,Heart,Conventional,General,Gastric,30%,,,40 Gy,45 Gy,,,TOPGEAR,,,,,,,
359,Heart,Conventional,General,Esophageal,50%,,,30 Gy,,,,RTOG 1308,,,,,,,
360,Heart,Conventional,General,Esophageal,100%,,,30 Gy,,,,RTOG 1010,,,,,,,
361,Heart,Conventional,General,Esophageal,77%,,,20 Gy,,,,,,,Pao Rad Onc '20,https://pubmed.ncbi.nlm.nih.gov/32962730/,,,
362,Heart,Conventional,General,Esophageal,86%,,,10 Gy,,,,,,,Pao Rad Onc '20,https://pubmed.ncbi.nlm.nih.gov/32962730/,,,
363,Heart,Conventional,General,Esophageal,94%,,,5 Gy,,,,,,,Pao Rad Onc '20,https://pubmed.ncbi.nlm.nih.gov/32962730/,,,
364,Heart,8,General,,n/a,,,n/a,,,,LungTECH,,,,,,,
365,Heart,15-16,General,,Max,,,66 Gy,,,,SUNSET,,,,,,,
366,Heart,15-16,General,,10 cc,,,62 Gy,,,,SUNSET,,,,,,,
367,Heart,15-16,General,,Max,,,55 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
368,Heart,15-16,General,,1 cc,,,50 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
369,Heart,15-16,General,,Max,,,49.8 Gy,52 Gy,,,NRG LU004,,,,,,,
370,Heart,15-16,General,,10%,,,40 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
371,Heart,15-16,General,,Max,,,40 Gy,50 Gy,,,,,,NCIC CTV BR.25,https://academic.oup.com/jnci/article/106/8/dju164/910382,,,
372,Heart,15-16,General,,Mean,,,16.5 Gy,18.5 Gy,,,NRG LU004,,,,,,,
373,Heart,Conventional,General,Breast,Mean,,,4 Gy,5 Gy,,,"RTOG 1005,NSABP B-51",,,,,,,
374,Heart,Conventional,General,Breast,Max,,,35 Gy,40 Gy,,,,,,Needs source,,,,
375,Heart,Conventional,General,Breast,5%,,,40 Gy,,,,DBCG SKAGEN,,,,,,,
376,Heart,Conventional,General,Breast,10%,,,20 Gy,,,,DBCG SKAGEN,,,,,,,
377,Heart,15-16,General,Breast,5%,,,16 Gy,20 Gy,,,RTOG 1005,,,,,,,Left sided
378,Heart,15-16,General,Breast,30%,35%,,8 Gy,,,,RTOG 1005,,,,,,,Left sided
379,Heart,15-16,General,Breast,0%,,,16 Gy,20 Gy,,,RTOG 1005,,,,,,,Right sided
380,Heart,15-16,General,Breast,10%,15%,,8 Gy,,,,RTOG 1005,,,,,,,Right sided
381,Heart,15-16,General,Breast,Mean,,,3.2 Gy,4 Gy,,,RTOG 1005,,,,,,,
382,Heart,Conventional,General,Breast,5%,,,20 Gy,25 Gy,,,"RTOG 1005,NSABP B-51",,,,,,,Left sided; 25 Gy if RNI
383,Heart,Conventional,General,Breast,30%,35%,,10 Gy,15 Gy,,,"RTOG 1005,NSABP B-51",,,,,,,Left sided; 15 Gy if RNI
384,Heart,Conventional,General,Breast,0%,,,20 Gy,25 Gy,,,"RTOG 1005,NSABP B-51",,,,,,,Right sided; 25 Gy if RNI
385,Heart,Conventional,General,Breast,10%,15%,,10 Gy,15 Gy,,,"RTOG 1005,NSABP B-51",,,,,,,Right sided; 15 Gy if RNI
386,Heart,5,General,Breast,5%,,,7 Gy,,,,UK FAST-Forward,,,,,,,
387,Heart,5,General,Breast,30%,,,1.5 Gy,,,,UK FAST-Forward,,,,,,,
388,Heart,5,General,Breast,10%,,,3 Gy,,,,Florence,,,,,,,
389,Heart,10,General,Breast,Max,,,36 Gy,,,,,,,MSKCC Braunstein IJROBP '19,https://www.sciencedirect.com/science/article/pii/S0360301619303062?via%3Dihub,,,
390,Heart,Conventional,General,"Gastric,Esophageal",Mean,,,30 Gy,,,,RTOG 1010,,,Gastric NCCN 1.2021,,Esophageal and GEJ NCCN 1.2021,,
391,Heart,Conventional,General,"Gastric,Esophageal",20%,30%,,30 Gy,,,,,,,Gastric NCCN 1.2021,,Esophageal and GEJ NCCN 1.2021,,
392,Heart,Conventional,General,Pediatrics,Mean,,,5 Gy,15 Gy,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,
393,Heart,Conventional,General,Pediatrics,10%,35%,,15 Gy,,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Wirth IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/32272184,Note: 25-35% is in the relapsed/refractory setting
394,Heart,Conventional,General,Pediatrics,15%,20%,,30 Gy,,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Wirth IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/32272184,Note: 20% is in the relapsed/refractory setting
1161,Heart,Conventional,General,Pediatrics,100%,,,30 Gy,,,,AEWS 1031,,,,,,,
1184,Heart,Conventional,General,Breast,Mean,,,4 Gy,5 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
1191,Heart,Conventional,General,Breast,0%,,,25 Gy,30 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT; Right sided
1192,Heart,Conventional,General,Breast,5%,,,25 Gy,30 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT; Left sided
395,Pericardium,Conventional,General,NSCLC,MOH55%,,,41 Gy,51 Gy,,,,,,Thor Clin Ca Res '10,https://pubmed.ncbi.nlm.nih.gov/32398326/,,,No CHD
396,Great_Vessels,1,General,,Max,,,37 Gy,,,,"RTOG 0631,RTOG 0915,BR002","Timmerman,TG-101",,,,,,
397,Great_Vessels,1,General,,10 cc,,,31 Gy,,,,"RTOG 0631,RTOG 0915,BR002",TG-101,,,,,,
398,Great_Vessels,3,General,,Max,,,45 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
399,Great_Vessels,3,General,,10 cc,,,39 Gy,,,,BR002,TG-101,,,,,,
400,Great_Vessels,3,General,,0.5 cc,,,45 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
401,Great_Vessels,5,General,NSCLC,Max,,,62 Gy,,,,SUNSET,,,,,,,
402,Great_Vessels,5,General,NSCLC,0.05 cc,,,52.5 Gy,63 Gy,,,RTOG 0813,,,,,,,
403,Great_Vessels,5,General,NSCLC,10 cc,,,50 Gy,,,,SUNSET,,,,,,,
404,Great_Vessels,5,General,,10 cc,,,47 Gy,,,,"BR002,RTOG 0813",TG-101,,,,,,
405,Great_Vessels,5,General,,0.5 cc,,,53 Gy,,,,BR002,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101,Timmerman",,,,,,
406,Great_Vessels,8,General,,Max,,,63 Gy,,Extrapolation,,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
407,Great_Vessels,8,General,,10 cc,,,56.8 Gy,,Extrapolation,,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
408,Great_Vessels,10,General,,Max,,,75 Gy,,Extrapolation,,RTOG 0813,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
409,Great_Vessels,10,General,,1 cc,,,50 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
410,Great_Vessels,10,General,,10 cc,,,63.5 Gy,,,,,,,Needs source,,,,
411,Great_Vessels,10,General,,Max,,,64 Gy,,,,SUNSET,,,,,,,
412,Great_Vessels,10,General,,10 cc,,,60 Gy,,,,SUNSET,,,,,,,
413,Great_Vessels,8,General,,n/a,,,n/a,,,,LungTECH,,,,,,,
414,Great_Vessels,15-16,General,,Max,,,64 Gy,,,,SUNSET,,,,,,,
415,Great_Vessels,15-16,General,,10 cc,,,60 Gy,,,,SUNSET,,,,,,,
416,Great_Vessels,15-16,General,,Max,,,53.5 Gy,55 Gy,,,NRG LU004,,,,,,,
417,L_Circumflex,Conventional,General,NSCLC,14%,,,15 Gy,,,,,,,Atkins JAMA Onc '20,https://pubmed.ncbi.nlm.nih.gov/33331883/,,,No CHD
418,LAD,Conventional,General,NSCLC,10%,,,15 Gy,,,,,,,Atkins JAMA Onc '20,https://pubmed.ncbi.nlm.nih.gov/33331883/,,,
419,Heart_Atria,Conventional,General,NSCLC,D45,,,30 Gy,44 Gy,,,,,,Thor Clin Ca Res '10,https://pubmed.ncbi.nlm.nih.gov/32398326/,,,No CHD
420,L_Ventricle,Conventional,General,NSCLC,1%,,,15 Gy,,,,,,,Atkins JAMA Onc '20,https://pubmed.ncbi.nlm.nih.gov/33331883/,,,
421,L_Ventricle,Conventional,General,NSCLC,MOH5%,,,41 Gy,56 Gy,,,,,,Thor Clin Ca Res '10,https://pubmed.ncbi.nlm.nih.gov/32398326/,,,
422,L_Ventricle,Conventional,General,Breast,10%,,,5 Gy,,,,,,,Needs source,,,,LV and combined bilateral ventricles
423,L_Ventricle,Conventional,General,Breast,5%,,,25 Gy,,,,,,,Needs source,,,,LV and combined bilateral ventricles
424,L_Ventricle,Conventional,General,Pediatrics,Mean,,,2 Gy,10 Gy,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,
425,Trachea,1,General,,Max,,,20.2 Gy,,,,"RTOG 0915,BR002,RTOG 0631","TG-101,Timmerman",,,,,,
426,Trachea,1,General,,4 cc,,,10.5 Gy,,,,,TG-101,,,,,,
427,Trachea,1,General,,4 cc,,,17.4 Gy,,,,BR002,Timmerman,,,,,,
428,Trachea,3,General,,Max,,,30 Gy,,,,BR002,TG-101,,,,,,
429,Trachea,3,General,,4 cc,,,15 Gy,,,,,TG-101,,,,,,
430,Trachea,3,General,,5 cc,,,25.8 Gy,,,,BR002,Timmerman,,,,,,
431,Trachea,3,General,,0.5 cc,,,30 Gy,32 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
432,Trachea,5,General,NSCLC,Max,,,60 Gy,,,,SUNSET,,,,,,,
433,Trachea,5,General,NSCLC,10 cc,,,50 Gy,,,,SUNSET,,,,,,,
434,Trachea,5,General,,5 cc,,,32 Gy,,,,BR002,,,,,,,
435,Trachea,5,General,,4 cc,,,16.5 Gy,18 Gy,,,RTOG 0813,TG-101,,,,,,
436,Trachea,5,General,NSCLC,0.05 cc,,,52.5 Gy,63 Gy,,,RTOG 0813,,,,,,,Limit to 105% of Rx (50-60 Gy)
437,Trachea,5,General,NSCLC,0.03 cc,,,50 Gy,,,,,,,Manyam IJROBP '20,https://pubmed.ncbi.nlm.nih.gov/31987965/,,,
438,Trachea,5,General,NSCLC,0.33 cc,,,47.1 Gy,,,,,,,Manyam IJROBP '20,https://pubmed.ncbi.nlm.nih.gov/31987965/,,,
439,Trachea,5,General,,Max,,,40 Gy,,,,BR002,"Timmerman,TG-101",,,,,,
440,Trachea,5,General,,0.5 cc,,,32 Gy,35 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
441,Trachea,8,General,NSCLC,Max,,,64 Gy,,,,SUNSET,,,,,,,
442,Trachea,8,General,,0.5 cc,,,32 Gy,44 Gy,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
443,Trachea,8,General,,Max,,,44 Gy,46.68 Gy,,,LungTECH,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
444,Trachea,8,General,NSCLC,10 cc,,,60 Gy,,,,SUNSET,,,,,,,
445,Trachea,8,General,,4 cc,,,20.8 Gy,,Extrapolation,,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
446,Trachea,8,General,NSCLC,Max,,,63 Gy,,Extrapolation,,RTOG 0813,,,VUMC Tekatli RTO '15,https://www.sciencedirect.com/science/article/abs/pii/S0167814015005101?via%3Dihub,,,
447,Trachea,10,General,NSCLC,Max,,,64 Gy,,,,SUNSET,,,,,,,
448,Trachea,10,General,NSCLC,10 cc,,,60 Gy,,,,SUNSET,,,,,,,
449,Trachea,10,General,,1.0 cc,,,40  Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
450,Trachea,10,General,,4 cc,,,20.6 Gy,,,,,,,Needs source,,,,
451,Trachea,10,General,NSCLC,Max,,,60 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
452,Trachea,15-16,General,,Max,,,66 Gy,,,,SUNSET,,,Needs source,,,,
453,Trachea,15-16,General,,10 cc,,,62 Gy,,,,SUNSET,,,Needs source,,,,
454,Trachea,15-16,General,NSCLC,Max,,,52 Gy,53.5 Gy,,,NRG LU004,,,Needs source,,,,
455,Trachea,15-16,General,NSCLC,Max,,,40 Gy,50 Gy,,,,,,NCIC CTV BR.25,https://academic.oup.com/jnci/article/106/8/dju164/910382,,,
456,Trachea,2,General,,Max,,,20 Gy,,,,SC.24,,,,,,,
457,Bronchial_Tree,Conventional,General,,Max,,,80 Gy,,,,,QUANTEC,,,,,,
458,Bronchial_Tree,1,General,,Max,,,13.3 Gy,,,,,TG-101,,,,,,
459,Bronchial_Tree,1,General,,0.5 cc,,,12.4 Gy,,,,,TG-101,,,,,,
460,Bronchial_Tree,3,General,,Max,,,23.1 Gy,,,,,TG-101,,,,,,
461,Bronchial_Tree,3,General,,0.5 cc,,,18.9 Gy,,,,,TG-101,,,,,,
462,Bronchial_Tree,5,General,,Max,,,33 Gy,,,,,TG-101,,,,,,
463,Bronchial_Tree,5,General,,0.5 cc,,,21 Gy,,,,,TG-101,,,,,,
464,Bronchial_Tree,10,General,,Max,,,60 Gy,,,,,,,,,,,
465,Bronchial_Tree,10,General,,1 cc,,,50 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
466,Bronchial_Tree,Conventional,General,,12%,,,75 Gy,,,,,,,Wang IJROBP '20,https://pubmed.ncbi.nlm.nih.gov/32470501/,,,
467,Bronchial_Tree,5,General,,Max,,,38 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
468,Bronchial_Tree,15-16,General,,Max,,,40 Gy,50 Gy,,,,,,NCIC CTV BR.25,https://academic.oup.com/jnci/article/106/8/dju164/910382,,,
469,Bronchial_Tree,2,General,,Max,,,20 Gy,,,,SC.24,,,,,,,
470,Lungs,Conventional,General,"Esophageal,NSCLC,Gastric",Mean,,,20 Gy,,,,"RTOG 0617,RTOG 1308,RTOG 1010",QUANTEC,,Gastric NCCN 1.2021,,Esophageal and GEJ NCCN 1.2021,,V20 < 30-35% and MLD < 20 Gy has a 20% risk of symptomatic RP. 
471,Lungs,Conventional,General,,Mean,,,15 Gy,17 Gy,,,,QUANTEC,,Thor Clin Ca Res '20,https://pubmed.ncbi.nlm.nih.gov/32398326/,,,
472,Lungs,Conventional,General,Esophageal,Mean,,,12.7 Gy,,,,,QUANTEC,,Pao Rad Onc '20,https://pubmed.ncbi.nlm.nih.gov/32962730/,,,
473,Lungs,Conventional,General,NSCLC,Mean,,,10 Gy,,,,,,,STRIPE,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448004/,,,If > 65y and receiving CCRT with CarboP
474,Lungs,Conventional,General,"NSCLC,Pediatrics",37%,40%,,20 Gy,,,,"RTOG 0617,RTOG 1308",QUANTEC,,,,,,V20 < 30-35% and MLD < 20 Gy has a 20% risk of symptomatic RP. 
475,Lungs,Conventional,General,"Esophageal,Pediatrics",25%,30%,,20 Gy,,,,"RTOG 1010,TOPGEAR,ANBL 1531",,,,,,,
476,Lungs,Conventional,General,"Esophageal,Gastric",40%,,,10 Gy,,,,RTOG 1010,,,Esophageal and GEJ NCCN 1.2021,,,,
477,Lungs,Conventional,General,,60%,65%,,5 Gy,,,,RTOG 1308,QUANTEC,,,,,,
478,Lungs,Conventional,General,,50%,,,5 Gy,,,,RTOG 1010,QUANTEC,,Esophageal and GEJ NCCN 1.2021,,,,
479,Lungs,Conventional,Postop,NSCLC,36%,,,5 Gy,,,,,,,Shepherd PRO '21,https://www.sciencedirect.com/science/article/pii/S1879850020302514?via%3Dihub,,,If > 65y and receiving PORT
480,Lungs,1,General,,37%,,,8 Gy,,,,BR002,Timmerman,,,,,,
481,Lungs,1,General,,*1500 cc,,,7 Gy,,,,BR002,TG-101,,,,,,
482,Lungs,1,General,,*1000 cc,,,7.4 Gy,,,,,TG-101,,,,,,
483,Lungs,1,General,,*1000 cc,,,7.6 Gy,,,,BR002,Timmerman,,,,,,
484,Lungs,3,General,,15%,,,20 Gy,,,,"BR002,RTOG 0618",,,,,,,
485,Lungs,3,General,,10%,,,20 Gy,,,,RTOG 0618,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
486,Lungs,3,General,,*1000 cc,,,12.4 Gy,,,,,TG-101,,,,,,
487,Lungs,3,General,,*1000 cc,,,11.4 Gy,,,,BR002,Timmerman,,,,,,
488,Lungs,3,General,,*37%,,,11 Gy,,,,BR002,Timmerman,,,,,,
489,Lungs,3,General,,*1500 cc,,,10.5 Gy,,,,BR002,Timmerman,,,,,,
490,Lungs,3,General,,*1500 cc,,,11.6 Gy,,,,,TG-101,,,,,,
491,Lungs,5,General,,Mean,,,6 Gy,,,,,,,Chang IJROBP '14,https://www.sciencedirect.com/science/article/pii/S0360301614000960?via%3Dihub,Ryckman Rad Onc '20,https://link.springer.com/epdf/10.1186/s13014-020-1479-6?author_access_token=8AacO02cYyFS78dlLFS8sW_BpE1tBhCbnbw3BuzI2RNZbLjtOl82FTiwcevk63KDECG2Dx0f70_Gz3so3wg-NOyj7IMssPDFsiPw7q3-THnX15EpcXcSsF3GqGFvDmKzyvrBqcsgilIPjMC9aF5O1Q%3D%3D,
492,Lungs,5,General,,Mean,,,12 Gy,,,,SUNSET,,,,,,,
493,Lungs,5,General,,10%,,,20 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
494,Lungs,5,General,,*1500 cc,,,12.5 Gy,,,,"RTOG 0813,BR002",TG-101,,,,,,
495,Lungs,5,General,,*1000 cc,,,13.5 Gy,,,,"RTOG 0813,BR002",TG-101,,,,,,
496,Lungs,5,General,,*37%,,,13.5 Gy,,,,BR002,Timmerman,,,,,,
497,Lungs,8,General,,Mean,,,12 Gy,,,,,,,Needs source,,,,
498,Lungs,8,General,,10%,,,20 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
499,Lungs,10,General,,Mean,,,9 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
500,Lungs,10,General,,*1000 cc,,,16.5 Gy,,,,,,,Needs source,,,,
501,Lungs,10,General,,Mean,,,12 Gy,,,,,,,Needs source,,,,
502,Lungs,10,General,,*1500 cc,,,15.2 Gy,,,,,,,Needs source,,,,
503,Lungs,10,General,,7%,,,40 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
504,Lungs,Conventional,General,Gastric,Mean,,,18 Gy,,,,TOPGEAR,QUANTEC,,,,,,
505,Lungs,15-16,General,,Mean,,,16.5 Gy,18.5 Gy,,,NRG LU004,,,,,,,
506,Lungs,15-16,General,,37%,40%,,16.5 Gy,,,,NRG LU004,,,,,,,
507,Lungs,15-16,General,,Mean,,,12 Gy,,,,,,,Kong IJROBP '20,https://doi.org/10.1016/j.ijrobp.2020.03.038,,,
508,Lungs,15-16,General,,Mean,,,14 Gy,,,,SUNSET,,,,,,,
509,Lungs,15-16,General,,65%,70%,,5 Gy,,,,NRG LU004,,,,,,,
510,Lungs,15-16,General,,40%,50%,,5 Gy,,,,,,,Kong IJROBP '20,https://doi.org/10.1016/j.ijrobp.2020.03.038,,,
511,Lungs,Conventional,General,Mesothelioma,Mean,,,8.5 Gy,,,,,,,MDACC Rice IJROBP '07,https://www.sciencedirect.com/science/article/pii/S0360301607005056?via%3Dihub,,,Mesothelioma after EPP
512,Lungs,Conventional,General,"Gastric,Esophageal",10%,,,40 Gy,,,,,,,Esophageal and GEJ NCCN 1.2021,,,,
513,Lungs,Conventional,General,"Gastric,Esophageal",15%,,,30 Gy,,,,,,,Esophageal and GEJ NCCN 1.2021,,,,
514,Lungs,Conventional,General,"Gastric,Esophageal,Pediatrics",20%,,,20 Gy,,,,"RTOG 0630,AEWS 1031",,,Esophageal and GEJ NCCN 1.2021,,,,
515,Lungs,Conventional,General,Pediatrics,20%,35%,,20 Gy,,,,AEWS 1031,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,
516,Lungs,Conventional,General,Pediatrics,35%,60%,,5 Gy,,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,
517,Lungs,Conventional,General,Pediatrics,Mean,,,8 Gy,13.5 Gy,,,,,,Wirth IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/32272184,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,
518,Lungs,2,General,,Mean,,,5 Gy,,,,SC.24,,,,,,,
519,Lungs,2,General,,10%,,,10 Gy,,,,SC.24,,,,,,,
520,Lungs,2,General,,35%,,,5 Gy,,,,SC.24,,,,,,,
521,Lungs,2,General,,3%,,,20 Gy,,,,SC.24,,,,,,,
1171,Lungs,Conventional,General,Pediatrics,100%,,,15 Gy,,,,AEWS 1031,,,,,,,
1176,Lungs,Conventional,General,"Gastric,Esophageal",50%,,,5 Gy,,,,,,,Esophageal and GEJ NCCN 1.2021,,,,
522,Lung_Ipsi,Conventional,General,Breast,15%,20%,,20 Gy,,,,"RTOG 1005,NSABP B-51,DBCG SKAGEN",,,,,,,No RNI
523,Lung_Ipsi,Conventional,General,Breast,35%,40%,,20 Gy,,,,"RTOG 1005,NSABP B-51,DBCG SKAGEN",,,,,,,Includes RNI
524,Lung_Ipsi,Conventional,General,Breast,35%,40%,,10 Gy,,,,"RTOG 1005,NSABP B-51",,,,,,,No RNI
525,Lung_Ipsi,Conventional,General,Breast,50%,60%,,10 Gy,,,,"RTOG 1005,NSABP B-51",,,,,,,Includes RNI
526,Lung_Ipsi,Conventional,General,Breast,50%,55%,,5 Gy,,,,"RTOG 1005,NSABP B-51",,,,,,,No RNI
527,Lung_Ipsi,Conventional,General,Breast,65%,70%,,5 Gy,,,,"RTOG 1005,NSABP B-51",,,,,,,Includes RNI
528,Lung_Ipsi,15-16,General,Breast,15%,20%,,16 Gy,,,,RTOG 1005,,,,,,,
529,Lung_Ipsi,15-16,General,Breast,35%,40%,,8 Gy,,,,RTOG 1005,,,,,,,
530,Lung_Ipsi,15-16,General,Breast,50%,55%,,4 Gy,,,,RTOG 1005,,,,,,,
531,Lung_Ipsi,5,General,Breast,15%,17%,,8 Gy,,,,UK FAST-Forward,,,,,,,
532,Lung_Ipsi,5,General,Breast,20%,,,10 Gy,,,,Florence,,,,,,,
533,Lung_Ipsi,10,General,Breast,3%,,,20 Gy,,,,,,,MSKCC Braunstein IJROBP '19,https://www.sciencedirect.com/science/article/pii/S0360301619303062?via%3Dihub,,,
534,Lung_Ipsi,Conventional,General,Pediatrics,30%,,,20 Gy,,,,ANBL 1531,,,,,,,No RNI
1185,Lung_Ipsi,Conventional,General,Breast,30%,35%,,20 Gy,,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
1186,Lung_Ipsi,Conventional,General,Breast,50%,60%,,10 Gy,,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
1187,Lung_Ipsi,Conventional,General,Breast,65%,75%,,5 Gy,,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
535,Lung_Contra,Conventional,General,,Mean,,,8 Gy,,,,,,,Needs source,,,,
536,Lung_Contra,Conventional,General,,7%,10%,,20 Gy,,,,,,,Needs source,,,,
537,Lung_Contra,Conventional,General,,13%,,,10 Gy,,,,,,,Needs source,,,,
538,Lung_Contra,Conventional,General,,60%,75%,,5 Gy,,,,,,,Needs source,,,,
539,Lung_Contra,Conventional,General,Breast,10%,15%,,5 Gy,,,,RTOG 1005,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Applies regardless of VMAT
540,Lung_Contra,Conventional,General,Breast,5%,,,20 Gy,,,,,,,Needs source,,,,VMAT
541,Lung_Contra,15-16,General,Breast,10%,15%,,4 Gy,,,,RTOG 1005,,,,,,,
542,Lung_Contra,5,General,Breast,10%,,,5 Gy,,,,Florence,,,,,,,
543,Lung_Contra,Conventional,General,Mesothelioma,7%,,,20 Gy,,,,,,,MDACC Rice IJROBP '07,https://www.sciencedirect.com/science/article/pii/S0360301607005056?via%3Dihub,,,Mesothelioma after EPP
544,Lung_Contra,Conventional,General,Pediatrics,10%,,,20 Gy,,,,ANBL 1531,,,,,,,No RNI
545,Rib,1,General,,Max,,,33 Gy,,,,BR002,Timmerman,,,,,,
546,Rib,1,General,,Max,,,30 Gy,,,,,TG-101,,,,,,
547,Rib,1,General,,5 cc,,,28 Gy,,,,BR002,Timmerman,,,,,,
548,Rib,1,General,,1 cc,,,22 Gy,,,,,TG-101,,,,,,
549,Rib,3,General,,Max,,,50 Gy,,,,BR002,Timmerman,,,,,,
550,Rib,3,General,,30 cc,,,30 Gy,,,,,TG-101,,,,,,
551,Rib,3,General,,Max,,,36.9 Gy,,,,,TG-101,,,,,,
552,Rib,3,General,,5 cc,,,40 Gy,,,,BR002,Timmerman,,,,,,
553,Rib,5,General,,Max,,,57 Gy,,,,BR002,Timmerman,,,,,,
554,Rib,5,General,,5 cc,,,45 Gy,,,,BR002,Timmerman,,,,,,
555,Rib,5,General,,30 cc,,,35 Gy,,,,,TG-101,,,,,,
556,Rib,5,General,,Max,,,43 Gy,,,,,TG-101,,,,,,
557,Rib,10,General,,Max,,,57.6 Gy,,,,BR002,Timmerman,,,,,,
558,Rib,10,General,,1 cc,,,46 Gy,,,,,TG-101,,,,,,
559,Rib,3,General,,1 cc,,,28.8 Gy,,,,,TG-101,,,,,,
560,Chest_Wall,1,General,,Max,,,30 Gy,,,,,Timmerman,,,,,,
561,Chest_Wall,3,General,,0.5 cc,,,37 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
562,Chest_Wall,3,General,,30 cc,70 cc,,30 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
563,Chest_Wall,5,General,,Max,,,43 Gy,,,,,Timmerman,,,,,,
564,Chest_Wall,5,General,,0.5 cc,,,39 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
565,Chest_Wall,5,General,,30 cc,70 cc,,32 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
566,Chest_Wall,8,General,,0.5 cc,,,39 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
567,Chest_Wall,8,General,,30 cc,,,35 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
568,Chest_Wall,10,General,,Max,,,82 Gy,,Extrapolation,,RTOG 0813,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
569,Chest_Wall,10,General,,120 cc,,,40 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
570,Chest_Wall,10,General,,60 cc,,,50 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
571,Chest_Wall,10,General,,250 cc,,,30 Gy,,,,,,,MDACC Chang JTO '15,https://pubmed.ncbi.nlm.nih.gov/25514807/,,,
572,Chest_Wall,8,General,,n/a,,,n/a,,,,LungTECH,,,,,,,
573,Breast,5,General,,Max,,,48 Gy,,,,,,,Rahimi IJROBP ‘20,https://pubmed.ncbi.nlm.nih.gov/32464155/,,,
574,Breast,5,General,,1 cc,,,47.5 Gy,,,,,,,Rahimi IJROBP ‘20,https://pubmed.ncbi.nlm.nih.gov/32464155/,,,
575,Breast,5,General,,20 cc,,,45 Gy,,,,,,,Rahimi IJROBP ‘20,https://pubmed.ncbi.nlm.nih.gov/32464155/,,,
576,Breast,5,General,,50 cc,,,42.5 Gy,,,,,,,Rahimi IJROBP ‘20,https://pubmed.ncbi.nlm.nih.gov/32464155/,,,PTV < 100 cc
577,Breast,Conventional,General,Pediatrics,Max,,,4 Gy,15 Gy,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,Breast tissue growth and development affected at 5-10 Gy
578,Breast,Conventional,General,Pediatrics,10%,20%,,4 Gy,,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,Breast tissue growth and development affected at 5-10 Gy
579,Breast,Conventional,General,Pediatrics,10%,,,10 Gy,,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,Breast tissue growth and development affected at 5-10 Gy
580,Breast,Conventional,General,Pediatrics,55%,60%,,5 Gy,,,,,,Must,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,Italian Expert Consensus,https://www.ncbi.nlm.nih.gov/pubmed/32164700,Breast tissue growth and development affected at 5-10 Gy
581,Breast_Ipsi,Conventional,General,Breast,10%,,,105%,,,,,,,Patel IJROBP '19,https://pubmed.ncbi.nlm.nih.gov/30145393/,,,
582,Breast_Ipsi,5,General,Breast,5%,,,105%,,,,Florence,,,,,,,
583,Breast_Ipsi,5,General,Breast,50%,,,15 Gy,,,,Florence,,,,,,,Ipsi breast - PTV
584,Breast_Ipsi,10,General,Breast,45%,50%,,20 Gy,,,,,,,MSKCC Braunstein IJROBP '19,https://www.sciencedirect.com/science/article/pii/S0360301619303062?via%3Dihub,,,Ipsi breast - PTV
585,Breast_Contra,Conventional,General,Breast,Max,,,3.1 Gy,4.96 Gy,,,,,,Needs source,,,,
586,Breast_Contra,Conventional,General,Breast,5%,,,1.86 Gy,3.1 Gy,,,"RTOG 1005,NSABP B-51",,,,,,,
587,Breast_Contra,Conventional,General,Breast,Mean,,,6 Gy,,,,,,,,,,,VMAT
588,Breast_Contra,15-16,General,Breast,Max,,,2.4 Gy,3.84 Gy,,,RTOG 1005,,,,,,,
589,Breast_Contra,15-16,General,Breast,5%,,,1.44 Gy,2.40 Gy,,,RTOG 1005,,,,,,,
590,Breast_Contra,5,General,Breast,Max,,,1 Gy,,,,Florence,,,,,,,VMAT
1189,Breast_Contra,Conventional,General,Breast,5%,10%,,4.1 Gy,,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
591,Stomach,Conventional,General,"Pancreas,Gastric",Max,,,54 Gy,55 Gy,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,Esophageal and GEJ NCCN 1.2021,,
592,Stomach,Conventional,General,,Max,,,45 Gy,50 Gy,,,,QUANTEC,,,,,,Stomach D100 to 45 Gy with < 7% gastric ulceration.
593,Stomach,Conventional,General,,10%,,,54 Gy,,,,,,,Needs source,,,,
594,Stomach,Conventional,General,,10%,15%,,50 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
595,Stomach,Conventional,General,,1 cc,,,50 Gy,,,,,,,Needs source,,,,
596,Stomach,Conventional,General,,15%,,,45 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
597,Stomach,Conventional,General,,50%,,,20 Gy,,,,,,,Needs source,,,,
598,Stomach,1,General,,Max,,,22 Gy,,,,BR002,Timmerman,,,,,,
599,Stomach,1,General,,Max,,,12.4 Gy,,,,,TG-101,,,,,,
600,Stomach,1,General,,5 cc,,,15.4 Gy,17.4 Gy,,,"BR002,IROCK: Solitary Kidney",Timmerman,,,,,,Stomach V22.5 < 5 cc (4%) - QUANTEC
601,Stomach,1,General,,10 cc,,,11.2 Gy,,,,RTOG 0631,TG-101,,,,,,
602,Stomach,3,General,,Max,,,30 Gy,,,,"BR002,IROCK: Solitary Kidney",Timmerman,,,,,,
603,Stomach,3,General,,Max,,,22.2 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
604,Stomach,3,General,,10 cc,,,22.5 Gy,,,,BR002,TG-101,,,,,,
605,Stomach,3,General,,10 cc,,,16.5 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
606,Stomach,5,General,,10 cc,,,35 Gy,,,,SUNSET,,,,,,,
607,Stomach,5,General,,5 cc,,,26.5 Gy,,,,BR002,Timmerman,,,,,,
608,Stomach,5,General,,Max,,,32 Gy,,,,,TG-101,,,,,,
609,Stomach,5,General,,10 cc,,,18 Gy,,,,,TG-101,,,,,,
610,Stomach,5,General,,0.5 cc,,,33 Gy,35 Gy,,,BR002,"Timmerman,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
611,Stomach,5,General,,5 cc,10 cc,,25 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
612,Stomach,5,General,,50 cc,,,12 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
613,Stomach,8,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
614,Stomach,8,General,,10 cc,,,40 Gy,,,,SUNSET,,,,,,,
615,Stomach,10,General,,Max,,,41.9 Gy,,,,,,,Needs source,,,,
616,Stomach,10,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
617,Stomach,10,General,,10 cc,,,40 Gy,,,,SUNSET,,,,,,,
618,Stomach,10,General,,1 cc,,,37 Gy,,,,RTOG 0438,,,,,,,
619,Stomach,10,General,,10 cc,,,22.6 Gy,,,,,,,Needs source,,,,
620,Stomach,Conventional,General,Gastric,Max,,,48.2 Gy,,,,TOPGEAR,,,,,,,Stomach D100 to 45 Gy with < 7% gastric ulceration.
621,Stomach,Conventional,General,,75 cc,,,45 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
622,Stomach,5,General,Pancreas,0.5 cc,,0.5 cm,40 Gy,,,,SUNSET,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
623,Stomach,5,General,Pancreas,1 cc,,0.5 cm,35 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
624,Stomach,5,General,Pancreas,2 cc,,0.5 cm,30 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
625,Stomach,5,General,Pancreas,1 cc,,,33 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,,,
626,Stomach,5,General,Pancreas,3 cc,,,20 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,,,
627,Stomach,5,General,Pancreas,9 cc,,,15 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,,,
628,Stomach,15-16,General,,Max,,,50 Gy,,,,SUNSET,,,,,,,
629,Stomach,15-16,General,,10 cc,,,48 Gy,,,,SUNSET,,,,,,,
630,Stomach,15-16,General,,Max,,,45 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
631,Stomach,Conventional,General,Gastric,Min,,,40.5 Gy,,,,TOPGEAR,,,,,,,Stomach D100 to 45 Gy with < 7% gastric ulceration.
632,Stomach,Conventional,General,Gastric,Mean,,,30 Gy,,,,,,,Esophageal and GEJ NCCN 1.2021,,,,Stomach - PTV
633,Stomach,5,General,Pancreas,20 cc,,0.5 cm,20 Gy,,,,,,,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,,,
634,Stomach,Conventional,General,Sarcoma,33%,,,60 Gy,,,,,,,Needs source,,,,
635,Stomach,Conventional,General,Sarcoma,67%,,,55 Gy,,,,,,,Needs source,,,,
636,Stomach,Conventional,General,Sarcoma,100%,,,50 Gy,,,,,,,Needs source,,,,
637,Stomach,2,General,,Max,,,20 Gy,,,,SC.24,,,,,,,
638,Duodenum,Conventional,General,,Max,,,50 Gy,,,,,,,Needs source,,,,
639,Duodenum,Conventional,General,Gynecological,2 cc,,,60 Gy,,,,,,,Verma IJROBP '14,https://www.sciencedirect.com/science/article/pii/S0360301613032793?via%3Dihub,,,3y G2+ for D2cc ± 60 Gy of 4→ 19%
640,Duodenum,Conventional,General,Gynecological,15 cc,,,55 Gy,,,,EMBRACE II,,Must,Verma IJROBP '14,https://www.sciencedirect.com/science/article/pii/S0360301613032793?via%3Dihub,,,3y G2+ for V55 ± 15 cc of 7→ 49% 
641,Duodenum,Conventional,General,Gynecological,1 cc,,,55 Gy,,,,,,,George Clin Onc '20,https://www.ncbi.nlm.nih.gov/pubmed/31495648,,,G2+ for V55 1 / 10cc of 10→ 20%
642,Duodenum,Conventional,General,Gynecological,4 cc,,,50 Gy,,,,,,,George Clin Onc '20,https://www.ncbi.nlm.nih.gov/pubmed/31495648,,,G2+ for V50 4 / 10cc of 10→ 14%
643,Duodenum,1,General,,10 cc,,,9 Gy,,,,BR002,"TG-101,Timmerman",,,,,,
644,Duodenum,1,General,,5 cc,,,11.2 Gy,,,,"BR002,RTOG 0631",TG-101,,,,,,
645,Duodenum,1,General,,Max,,,12.4 Gy,,,,,"TG-101,QUANTEC",,,,,,Small bowel receiving 12.5 Gy should be < 30 cc with avoidance of circumferential coverage above that dose.
646,Duodenum,1,General,,Max,,,16 Gy,17 Gy,,,"BR002,RTOG 0631",Timmerman,,,,,,
647,Duodenum,3,General,,10 cc,,,15 Gy,,,,BR002,Timmerman,,,,,,
648,Duodenum,3,General,,5 cc,,,16.5 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
649,Duodenum,3,General,,Max,,,24 Gy,,,,BR002,Timmerman,,,,,,
650,Duodenum,3,General,,Max,,,30 Gy,,,,IROCK: Solitary Kidney,,,,,,,
651,Duodenum,3,General,,Max,,,22.2 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
652,Duodenum,3,General,,10 cc,,,11.4 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
653,Duodenum,5,General,,5 cc,,,18 Gy,18.3 Gy,,,BR002,"TG-101,Timmerman",,,,,,
654,Duodenum,5,General,,10 cc,,,12.5 Gy,,,,,TG-101,,,,,,
655,Duodenum,5,General,,0.5 cc,,,30 Gy,,,,"RTOG 1112,BR002",,,,,,,
656,Duodenum,5,General,,0.5 cc,,,35 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
657,Duodenum,5,General,,10 cc,,,35 Gy,,,,SUNSET,,,,,,,
658,Duodenum,5,General,,Max,,,32 Gy,,,,,TG-101,,,,,,
659,Duodenum,5,General,,5 cc,10 cc,,25 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
660,Duodenum,8,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
661,Duodenum,8,General,,10 cc,,,40 Gy,,,,SUNSET,,,,,,,
662,Duodenum,10,General,,Max,,,41.9 Gy,,,,,,,Needs source,,,,
663,Duodenum,10,General,,10 cc,,,15.2 Gy,,,,,,,Needs source,,,,
664,Duodenum,10,General,,5 cc,,,22.6 Gy,,,,,,,Needs source,,,,
665,Duodenum,10,General,,1 cc,,,37 Gy,,,,RTOG 0438,,,,,,,
666,Duodenum,10,General,,10 cc,,,40 Gy,,,,SUNSET,,,,,,,
667,Duodenum,10,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
668,Duodenum,Conventional,General,Pancreas,Max,,,55 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
669,Duodenum,Conventional,General,Pancreas,Full Circumference,,,50 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
670,Duodenum,Conventional,General,Pancreas,10%,,,50 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
671,Duodenum,Conventional,General,Pancreas,10 cc,,,50 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
672,Duodenum,Conventional,General,Pancreas,15%,,,45 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,
673,Duodenum,1,General,Pancreas,Max,,,23 Gy,,,,,,,Murphy IJROBP '09,https://www.sciencedirect.com/science/article/pii/S0360301609035226?via%3Dihub,,,G2+ duodenal toxicity for V15 ± 9.1 cc of 11→ 52%. Similar results for V20 ± 3.3 cc and Dmax ± 23 Gy.
674,Duodenum,1,General,Pancreas,3 cc,,,20 Gy,,,,,,,Murphy IJROBP '09,https://www.sciencedirect.com/science/article/pii/S0360301609035226?via%3Dihub,,,G2+ duodenal toxicity for V15 ± 9.1 cc of 11→ 52%. Similar results for V20 ± 3.3 cc and Dmax ± 23 Gy.
675,Duodenum,1,General,Pancreas,9 cc,,,15 Gy,,,,,,,Murphy IJROBP '09,https://www.sciencedirect.com/science/article/pii/S0360301609035226?via%3Dihub,,,G2+ duodenal toxicity for V15 ± 9.1 cc of 11→ 52%. Similar results for V20 ± 3.3 cc and Dmax ± 23 Gy.
676,Duodenum,5,General,Pancreas,0.5 cc,,0.5 cm,40 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
677,Duodenum,5,General,Pancreas,1 cc,,0.5 cm,35 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
678,Duodenum,5,General,Pancreas,3 cc,,0.5 cm,30 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
679,Duodenum,5,General,Pancreas,1 cc,,,33 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,,,
680,Duodenum,5,General,Pancreas,3 cc,,,20 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,,,
681,Duodenum,5,General,Pancreas,9 cc,,,15 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,,,
682,Duodenum,15-16,General,,Max,,,45 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
683,Duodenum,15-16,General,,Max,,,50 Gy,,,,SUNSET,,,,,,,
684,Duodenum,15-16,General,,10 cc,,,48 Gy,,,,SUNSET,,,,,,,
685,Duodenum,5,General,Pancreas,30 cc,,0.5 cm,20 Gy,,,,,,,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,,,
686,Spleen,Conventional,General,Pancreas,Mean,,,9 Gy,,,,,,,MDACC Chadha IJROBP '17,https://www.redjournal.org/article/S0360-3016(16)33422-8/abstract,,,
687,Spleen,Conventional,General,Pediatrics,Mean,,,10 Gy,,,,,,,SIOP Arunagiri EJC '21,https://pubmed.ncbi.nlm.nih.gov/33271483/,,,
688,Spleen,5,General,,Mean,,,2 Gy,,,,,,,Needs source,,,,
689,Spleen,Conventional,General,,20%,,,15 Gy,,,,,,,MDACC Chadha IJROBP '17,https://www.redjournal.org/article/S0360-3016(16)33422-8/abstract,,,
690,Spleen,15-16,General,Pancreas,Mean,,,6 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
691,Liver,Conventional,General,,Mean,,,25 Gy,32 Gy,,,RTOG 1010,QUANTEC,,Esophageal and GEJ NCCN 1.2021,,,,MLD of 30-32 Gy with < 5% RILD (excludes cirrhosis). MLD of 28 Gy with < 5% RILD in Child-Pugh A / HCC.
692,Liver,Conventional,General,,30%,,,36 Gy,40 Gy,,,,,,Needs source,,,,
693,Liver,Conventional,General,,66%,,,48 Gy,,,,,,,Needs source,,,,
694,Liver,Conventional,General,,60%,,,30 Gy,,,,RTOG 1010,,,,,,,
695,Liver,Conventional,General,,TD 5/5,,,30 Gy,,,,,QUANTEC,,,,,,
696,Liver,1,General,,*700 cc,,,9.1 Gy,,,,,TG-101,,,,,,
697,Liver,1,General,,*700 cc,,,11 Gy,,,,BR002,Timmerman,,,,,,
698,Liver,3,General,,*700 cc,,,19.2 Gy,,,,,TG-101,,,,,,
699,Liver,3,General,,*700 cc,,,17.1 Gy,,,,BR002,Timmerman,,,,,,
700,Liver,3,General,,*700 cc,,,15 Gy,19.2 Gy,,,IROCK: Solitary Kidney,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
701,Liver,3,General,,Mean,,,13 Gy,15 Gy,,,,,,Needs source,,,,
702,Liver,5,General,,Mean,,,13 Gy,17 Gy,,,RTOG 1112,,,,,,,
703,Liver,5,General,,*700 cc,,,21 Gy,,,,BR002,"TG-101,Timmerman",,,,,,
704,Liver,5,General,,70%,,,10 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
705,Liver,5,General,,60%,,,5 Gy,,,,,,,Pursley IJROBP '20,https://pubmed.ncbi.nlm.nih.gov/32353390/,,,
706,Liver,5,General,,Mean,,,15.2 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
707,Liver,10,General,,*700 cc,,,26.7 Gy,,,,,,,Needs source,,,,
708,Liver,10,General,,30%,,,27 Gy,,,,RTOG 0438,,,,,,,
709,Liver,10,General,,50%,,,24 Gy,,,,RTOG 0438,,,,,,,
710,Liver,Conventional,General,,33%,,,50 Gy,,,,TOPGEAR,,,,,,,
711,Liver,Conventional,General,,67%,,,35 Gy,,,,TOPGEAR,,,,,,,
712,Liver,Conventional,General,,30%,33%,,30 Gy,,,,,,,Gastric NCCN 1.2021,,,,
713,Liver,3,General,,*15%,,,15 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
714,Liver,15-16,General,Pancreas,700 cc,,,24 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
715,Liver,15-16,General,Pancreas,Mean,,,24 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
716,Liver,15-16,General,,60%,,,5 Gy,,,,,,,Pursley IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/32353390,,,
717,Liver,Conventional,General,"Gastric,Esophageal",20%,,,30 Gy,,,,,,,Esophageal and GEJ NCCN 1.2021,,,,
718,Liver,Conventional,General,"Gastric,Esophageal",30%,,,20 Gy,,,,,,,Esophageal and GEJ NCCN 1.2021,,,,
719,Liver,5,General,,50%,,,12 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
720,Liver,Conventional,General,Sarcoma,33%,,,60 Gy,,,,,,,Needs source,,,,
721,Liver,Conventional,General,Sarcoma,67%,,,47 Gy,,,,,,,Needs source,,,,
722,Liver,Conventional,General,Sarcoma,100%,,,31 Gy,,,,,,,Needs source,,,,
723,Liver,2,General,,Mean,,,8 Gy,,,,SC.24,,,,,,,
724,Liver,2,General,,Max,,,24 Gy,,,,SC.24,,,,,,,
725,Liver,2,General,,Max,,,24 Gy,,,,SC.24,,,,,,,
726,Liver,Conventional,General,Pediatrics,Max,,,23.4 Gy,,,,ARST 1431,,,,,,,
727,Liver,Conventional,General,Pediatrics,50%,,,30 Gy,,,,ARST 1431,,,,,,,
728,Liver,Conventional,General,Pediatrics,Mean,,,15 Gy,,,,ANBL 1531,,,,,,,
729,Liver,Conventional,General,Pediatrics,15%,,,30 Gy,,,,ANBL 1531,,,,,,,
1162,Liver,Conventional,General,Pediatrics,100%,,,23.4 Gy,,,,AEWS 1031,,,,,,,
1163,Liver,Conventional,General,Pediatrics,50%,,,30 Gy,,,,AEWS 1031,,,,,,,
730,Pancreas,Conventional,General,Pediatrics,Max,,,10 Gy,,,,ANBL 1531,,,,,,,Diabetes is seen with pancreas tail > 10 Gy.
731,Biliary_Tree,Conventional,General,,Max,,,80 Gy,,,,,,,Needs source,,,,
732,Biliary_Tree,1,General,,Max,,,30 Gy,,,,BR002,Timmerman,,,,,,
733,Biliary_Tree,3,General,,Max,,,36 Gy,,,,BR002,Timmerman,,,,,,
734,Biliary_Tree,3,General,,0.5 cc,,,50 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
735,Biliary_Tree,3,General,,21 cc,,,33.8 Gy,,,,,,,Osmundson IJROBP '15,https://www.ncbi.nlm.nih.gov/pubmed/25659885,,,
736,Biliary_Tree,3,General,,24 cc,,,32 Gy,,,,,,,Osmundson IJROBP '15,https://www.ncbi.nlm.nih.gov/pubmed/25659885,,,
737,Biliary_Tree,5,General,,24 cc,,,37.7 Gy,,,,,,,Osmundson IJROBP '15,https://www.ncbi.nlm.nih.gov/pubmed/25659885,,,
738,Biliary_Tree,5,General,,Max,,,41 Gy,,,,BR002,Timmerman,,,,,,
739,Biliary_Tree,5,General,,21 cc,,,40 Gy,,,,,,,Osmundson IJROBP '15,https://www.ncbi.nlm.nih.gov/pubmed/25659885,,,
740,Biliary_Tree,5,General,,0.5 cc,,,50 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
741,Biliary_Tree,15-16,General,Pancreas,Max,,,70 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
742,Renal_Cortex,Conventional,General,,Mean,,,18 Gy,,,,,QUANTEC,,,,,,Combined mean kidney dose of 18 / 28 Gy with < 5 → < 50% clinically relevant kidney dysfunction. 
743,Renal_Cortex,Conventional,General,,20%,,,30 Gy,,,,,QUANTEC,,,,,,Clinically relevant renal dysfunction < 5%
744,Renal_Cortex,Conventional,General,,30%,,,20 Gy,,,,RTOG 1010,QUANTEC,,,,,,Clinically relevant renal dysfunction < 5%
745,Renal_Cortex,Conventional,General,,33%,,,18 Gy,,,,,QUANTEC,,,,,,
746,Renal_Cortex,Conventional,General,,50%,67%,,18 Gy,,,,"RTOG 0418,RTOG 0724",QUANTEC,,,,,,
747,Renal_Cortex,1,General,,*200 cc,,,9.5 Gy,,,,BR002,Timmerman,,,,,,
748,Renal_Cortex,1,General,,*200 cc,,,8.4 Gy,,,,RTOG 0631,TG-101,,,,,,
749,Renal_Cortex,3,General,,*200 cc,,,15 Gy,16 Gy,,,BR002,"TG-101,Timmerman",,,,,,
750,Renal_Cortex,5,General,,*200 cc,,,17.5 Gy,18 Gy,,,BR002,TG-101,,,,,,
751,Renal_Cortex,5,General,,*200 cc,,,16 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
752,Renal_Cortex,5,General,,Mean,,,10 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
753,Renal_Cortex,10,General,,*200 cc,,,21.9 Gy,,,,,,,Needs source,,,,
754,Renal_Cortex,10,General,,10%,,,10 Gy,,,,RTOG 0438,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
755,Renal_Cortex,5,General,Pancreas,75%,,,12 Gy,,,,,,,Herman Ca '15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368473/,,,
756,Renal_Cortex,15-16,General,Pancreas,33%,,,20 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
757,Renal_Cortex,Conventional,General,"Esophageal,Gastric,Pediatrics",Mean,,,18 Gy,,,,,,,Gastric NCCN 1.2021,,Esophageal and GEJ NCCN 1.2021,,Each
758,Renal_Cortex,Conventional,General,"Esophageal,Gastric",33%,,,18 Gy,20 Gy,,,,,,Gastric NCCN 1.2021,,Esophageal and GEJ NCCN 1.2021,,Each
759,Renal_Cortex,Conventional,General,Gastric,33%,,,35 Gy,,,,TOPGEAR,,,,,,,Each
760,Renal_Cortex,Conventional,General,Gastric,67%,,,20 Gy,,,,TOPGEAR,,,,,,,Each
761,Renal_Cortex,Conventional,General,Gastric,Mean,,,23 Gy,,,,TOPGEAR,,,,,,,Each
762,Renal_Cortex,5,General,Pancreas,25%,,,12 Gy,,,,,,,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,,,
763,Renal_Cortex,Conventional,General,Cervix,Mean,,,10 Gy,15 Gy,,,EMBRACE II,,Must,,,,,Each
764,Renal_Cortex,Conventional,General,Sarcoma,33%,,,50 Gy,,,,,,,Needs source,,,,
765,Renal_Cortex,Conventional,General,Sarcoma,67%,,,30 Gy,,,,,,,Needs source,,,,
766,Renal_Cortex,Conventional,General,Sarcoma,100%,,,23 Gy,,,,,,,Needs source,,,,
767,Renal_Cortex,2,General,,Mean,,,5 Gy,,,,SC.24,,,,,,,
1168,Renal_Cortex,Conventional,General,Pediatrics,50%,,,24 Gy,,,,AEWS 1031,,,,,,,
1169,Renal_Cortex,Conventional,General,Pediatrics,100%,,,14.4 Gy,,,,AEWS 1031,,,,,,,
768,Renal_Cortex_Contra,Conventional,General,,Mean,,,9 Gy,,,,,,,Needs source,,,,
769,Renal_Cortex_Contra,Conventional,General,,15%,20%,,20 Gy,,,,RTOG 1010,,,,,,,
770,Renal_Cortex_Contra,Conventional,General,,10%,15%,,18 Gy,,,,,,,Needs source,,,,
771,Renal_Cortex_Contra,Conventional,General,Testicular,D50,,,8 Gy,,,,,,,,,,,
772,Renal_Cortex_Contra,Conventional,General,,30%,,,6 Gy,,,,,QUANTEC,,,,,,Clinically relevant renal dysfunction < 5%
773,Renal_Cortex_Contra,1,General,,33%,,,10 Gy,,,,IROCK: Solitary Kidney,,,,,,,
774,Renal_Cortex_Contra,Conventional,General,Pediatrics,25%,,,18 Gy,,,,ANBL 1531,,,,,,,
775,Renal_Cortex_Ipsi,5,General,,10%,45%,,10 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,If solitary kidney or one kidney mean dose > 10 Gy
776,Renal_Cortex_Ipsi,Conventional,General,Gastric,33%,,,35 Gy,,,,TOPGEAR,,,,,,,Clinically relevant renal dysfunction < 5%
777,Renal_Cortex_Ipsi,Conventional,General,Gastric,67%,,,20 Gy,,,,TOPGEAR,,,,,,,Clinically relevant renal dysfunction < 5%
778,Renal_Cortex_Ipsi,Conventional,General,Gastric,Mean,,,23 Gy,,,,TOPGEAR,,,,,,,Clinically relevant renal dysfunction < 5%
779,Renal_Cortex_Ipsi,Conventional,General,Pediatrics,D100,,,14.4 Gy,,,,"ARST 1431,ANBL 1531",,,,,,,
780,Renal_Cortex_Ipsi,Conventional,General,Pediatrics,D50,,,24 Gy,,,,ARST 1431,,,,,,,
781,Renal_Cortex_Ipsi,Conventional,General,Pediatrics,Mean,,,18 Gy,,,,ANBL 1531,,,,,,,
782,Renal_Cortex_Ipsi,Conventional,General,Pediatrics,75%,,,18 Gy,,,,ANBL 1531,,,,,,,
783,Renal_hilum,1,General,,Max,,,18.6 Gy,,,,,TG-101,,,,,,
784,Renal_hilum,1,General,,67%,,,10.6 Gy,,,,RTOG 0631,TG-101,,,,,,
785,Renal_hilum,1,General,,15 cc,,,14 Gy,,,,BR002,Timmerman,,,,,,
786,Renal_hilum,5,General,,15 cc,,,23 Gy,,,,BR002,Timmerman,,,,,,
787,Renal_hilum,3,General,,15 cc,,,19.5 Gy,,,,BR002,Timmerman,,,,,,
788,Renal_hilum,5,General,,67%,,,23 Gy,,,,,TG-101,,,,,,
789,Bowel_Bag,Conventional,General,,5 cc,10 cc,,50 Gy,,,,EMBRACE II,,Must,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,Bowel bag contour ends 2 cm above PTV
790,Bowel_Bag,Conventional,General,"Rectal,Anal,Gastric",195 cc,,,45 Gy,,,,,QUANTEC,,Roeske RTO '03,https://pubmed.ncbi.nlm.nih.gov/14643959/,Gastric NCCN 1.2021,,G3+ acute toxicity < 10% for bowel bag V45 < 195 cc.
791,Bowel_Bag,Conventional,General,Prostate,150 cc,200 cc,,45 Gy,,,,RTOG 0534 (SPPORT),,,,,,,Bowel bag contour ends 2 cm above PTV
792,Bowel_Bag,Conventional,General,,Max,,,50 Gy,52 Gy,,,"RTOG 0822,RTOG 0529",NRG Prostate,,,,,,Bowel bag contour ends 2 cm above PTV
793,Bowel_Bag,Conventional,General,,30%,70%,,40 Gy,,,,"RTOG 1203 (TIME-C),RTOG 0418,RTOG 0724,NRG GU001",,,,,,,Bowel bag contour ends 2 cm above PTV
794,Bowel_Bag,Conventional,General,"Pancreas,Rectal,Anal",Max,,,55 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,Bowel bag contour ends 2 cm above PTV
795,Bowel_Bag,Conventional,General,"Pancreas,Prostate",10%,,,50 Gy,,,,,NRG Prostate,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,Bowel bag contour ends 2 cm above PTV
796,Bowel_Bag,Conventional,General,Pancreas,15%,,,45 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,Bowel bag contour ends 2 cm above PTV
797,Bowel_Bag,Conventional,General,,2 cc,,,50 Gy,,,,,,,Jethwa ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673659/,,,Bowel bag contour ends 2 cm above PTV
798,Bowel_Bag,Conventional,General,Rectal,100 cc,,,40 Gy,,,,RTOG 0822,,,,,,,
799,Bowel_Bag,Conventional,General,Rectal,65 cc,,,45 Gy,,,,RTOG 0822,,,,,,,
800,Bowel_Bag,Conventional,General,"Gastric,Esophageal",D05,,,45 Gy,,,,,,,Esophageal and GEJ NCCN 1.2021,,,,Bowel bag contour ends 2 cm above PTV
801,Bowel_Bag,Conventional,General,Pancreas,10 cc,,,50 Gy,,,,,,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,,,Bowel bag contour ends 2 cm above PTV
802,Bowel_Bag,Conventional,General,Testicular,70%,,,20 Gy,,,,,,,,,,,Bowel bag contour ends 2 cm above PTV
803,Bowel_Bag,Conventional,General,Cervix,250 cc,300 cc,,40 Gy,,,,EMBRACE II,,Can,,,,,300 cc if pAO irradiation
804,Bowel_Bag,Conventional,General,Cervix,500 cc,650 cc,,30 Gy,,,,EMBRACE II,,Can,,,,,650 cc if pAO irradiation
805,Bowel_Bag,Conventional,General,Cervix,Max,,,105%,,,,EMBRACE II,,Must,,,,,"No 105% hot spot in bowel bag (e.g., 47.25 Gy for 45/25), or if node positive, Dmax < 105% in regions 1.0-1.5 cm from PTV-N"
806,Bowel_Bag,Conventional,General,Sarcoma,830 cc,,,15 Gy,,,,,,,Baldini IJROBP '15,https://www.redjournal.org/article/S0360-3016(15)00180-7/abstract,,,
1166,Bowel_Bag,Conventional,General,Pediatrics,75%,,,45 Gy,,,,AEWS 1031,,,,,,,
807,Bowel_Loop_Sm,Conventional,General,,120 cc,,,15 Gy,,,,,QUANTEC,,ESTRO ACROP Pancreas '20,https://pubmed.ncbi.nlm.nih.gov/32861703/,Baldini IJROBP '15,https://www.redjournal.org/article/S0360-3016(15)00180-7/abstract,G3+ acute toxicity < 10% for individual loops V15 < 120 cc
808,Bowel_Loop_Sm,1,General,,5 cc,,,11.9 Gy,,,,RTOG 0631,"TG-101,QUANTEC",,,,,,Small bowel receiving 12.5 Gy should be < 30 cc with avoidance of circumferential coverage above that dose. 
809,Bowel_Loop_Sm,1,General,,Max,,,15.4 Gy,,,,RTOG 0631,TG-101,,,,,,
810,Bowel_Loop_Sm,3,General,,0.5 cc,,,25.2 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
811,Bowel_Loop_Sm,3,General,,30 cc,,,12.5 Gy,,,,IROCK: Solitary Kidney,,,,,,,
812,Bowel_Loop_Sm,3,General,,5 cc,,,17.7 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
813,Bowel_Loop_Sm,3,General,,Max,,,30 Gy,,,,IROCK: Solitary Kidney,,,,,,,
814,Bowel_Loop_Sm,5,General,,5 cc,10 cc,,25 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
815,Bowel_Loop_Sm,5,General,,5 cc,,,19.5 Gy,,,,,TG-101,,,,,,
816,Bowel_Loop_Sm,5,General,,0.5 cc,,,30 Gy,35 Gy,,,,"UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,TG-101",,,,,,
817,Bowel_Loop_Sm,5,General,,10 cc,,,35 Gy,,,,SUNSET,,,,,,,
818,Bowel_Loop_Sm,8,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
819,Bowel_Loop_Sm,8,General,,10 cc,,,40 Gy,,,,SUNSET,,,,,,,
820,Bowel_Loop_Sm,10,General,,5 cc,,,24.6 Gy,,,,,,,Needs source,,,,
821,Bowel_Loop_Sm,10,General,,1 cc,,,37 Gy,,,,RTOG 0438,,,,,,,
822,Bowel_Loop_Sm,10,General,,10 cc,,,40 Gy,,,,SUNSET,,,,,,,
823,Bowel_Loop_Sm,10,General,,Max,,,45 Gy,,,,SUNSET,,,,,,,
824,Bowel_Loop_Sm,10,General,,Max,,,46 Gy,,,,,,,Needs source,,,,
825,Bowel_Loop_Sm,5,General,Pancreas,0.5 cc,,0.5 cm,40 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
826,Bowel_Loop_Sm,5,General,Pancreas,0.1 cc,1 cc,0.5 cm,35 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
827,Bowel_Loop_Sm,5,General,Pancreas,1 cc,3 cc,0.5 cm,30 Gy,,,,,,,Koay PRO '20,https://www.ncbi.nlm.nih.gov/pubmed/32061993,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,
828,Bowel_Loop_Sm,15-16,General,,Max,,,50 Gy,,,,SUNSET,,,,,,,
829,Bowel_Loop_Sm,15-16,General,,10 cc,,,48 Gy,,,,SUNSET,,,,,,,
830,Bowel_Loop_Sm,15-16,General,Pancreas,Max,,,45 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
831,Bowel_Loop_Sm,20,General,,Max,,,40 Gy,,,,,NRG Prostate,,,,,,
832,Bowel_Loop_Sm,20,General,,90 cc,,,37 Gy,,,,,NRG Prostate,,,,,,
833,Bowel_Loop_Sm,20,General,,130 cc,,,33 Gy,,,,,NRG Prostate,,,,,,
834,Bowel_Loop_Sm,5,General,Pancreas,15 cc,,0.5 cm,20 Gy,,,,,,,MDACC Colbert ARO '18,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200902/,,,
835,Bowel_Loop_Sm,28,General,Prostate,Max,,,52 Gy,,,,,NRG Prostate,,,,,,
836,Bowel_Loop_Sm,28,General,Prostate,2 cc,,,46 Gy,,,,,NRG Prostate,,,,,,
837,Bowel_Loop_Sm,28,General,Prostate,1%,,,40 Gy,,,,,,,Needs source,,,,
838,Bowel_Loop_Sm,5,General,Prostate,1 cc,,,30 Gy,,,,,,,Needs source,,,,
839,Bowel_Loop_Sm,5,General,Prostate,5 cc,,,18.1 Gy,,,,,,,Needs source,,,,
840,Bowel_Loop_Sm,Conventional,General,Sarcoma,33%,,,50 Gy,,,,,,,Needs source,,,,
841,Bowel_Loop_Sm,Conventional,General,Sarcoma,100%,,,40 Gy,,,,,,,Needs source,,,,
842,Bowel_Loop_Sm,Conventional,General,Sarcoma,20 cc,,,55 Gy,,,,,,,Baldini IJROBP '15,https://www.redjournal.org/article/S0360-3016(15)00180-7/abstract,,,
843,Bowel_Loop_Sm,Conventional,General,Sarcoma,120 cc,,,15 Gy,,,,,,,Baldini IJROBP '15,https://www.redjournal.org/article/S0360-3016(15)00180-7/abstract,,,
1143,Bowel_Loop_Sm,5,General,Rectal,180 cc,,,19.5 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1144,Bowel_Loop_Sm,5,General,Rectal,100 cc,,,22.2 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1145,Bowel_Loop_Sm,5,General,Rectal,65 cc,,,25 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1146,Bowel_Loop_Sm,5,General,Rectal,Max,,,27.8 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
844,Bowel_Loops,Conventional,General,"Anal,Rectal",200 cc,,,30 Gy,,,,RTOG 0529,,,Abraham PRO '20,https://pubmed.ncbi.nlm.nih.gov/32771626/,,,
845,Bowel_Loops,Conventional,General,"Anal,Rectal",150 cc,180 cc,,35 Gy,,,,"RTOG 0529,RTOG 0822",,,,,,,
846,Bowel_Loops,Conventional,General,Anal,20 cc,,,45 Gy,,,,RTOG 0529,,,,,,,
847,Bowel_Loops,Conventional,General,Anal,186 cc,,,25 Gy,,,,,,,Olsen IJROBP '17,https://www.redjournal.org/article/S0360-3016(17)30332-2/fulltext,,,"Small bowel V25 ≤ 186 cc, V30 ≤ 155 cc, V35 ≤ 41 cc, V40 ≤ 30.4 cc correlate to G2+ acute GI."
848,Bowel_Loops,Conventional,General,Anal,155 cc,,,30 Gy,,,,,,,Olsen IJROBP '17,https://www.redjournal.org/article/S0360-3016(17)30332-2/fulltext,,,"Small bowel V25 ≤ 186 cc, V30 ≤ 155 cc, V35 ≤ 41 cc, V40 ≤ 30.4 cc correlate to G2+ acute GI."
849,Bowel_Loops,Conventional,General,Anal,30.4 cc,,,40 Gy,,,,,,,Olsen IJROBP '17,https://www.redjournal.org/article/S0360-3016(17)30332-2/fulltext,,,"Small bowel V25 ≤ 186 cc, V30 ≤ 155 cc, V35 ≤ 41 cc, V40 ≤ 30.4 cc correlate to G2+ acute GI."
850,Bowel_Loops,Conventional,General,Rectal,100 cc,,,40 Gy,,,,RTOG 0822,,,,,,,
851,Bowel_Loops,Conventional,General,Rectal,65 cc,,,45 Gy,,,,RTOG 0822,,,,,,,
852,Bowel_Loops,Conventional,General,Bladder,116 cc,139 cc,,45 Gy,,,,RAIDER,,Must,,,,,
853,Bowel_Loops,Conventional,General,Bladder,104 cc,127 cc,,50 Gy,,,,RAIDER,,Must,,,,,
854,Bowel_Loops,Conventional,General,Bladder,91 cc,115 cc,,55 Gy,,,,RAIDER,,Must,,,,,
855,Bowel_Loops,Conventional,General,Bladder,73 cc,98 cc,,60 Gy,,,,RAIDER,,Must,,,,,
856,Bowel_Loops,Conventional,General,Bladder,23 cc,40 cc,,65 Gy,,,,RAIDER,,Must,,,,,
857,Bowel_Loops,Conventional,General,Bladder,0 cc,10 cc,,70 Gy,,,,RAIDER,,Must,,,,,
858,Bowel_Loops,Conventional,General,Bladder,0 cc,,,74 Gy,,,,RAIDER,,Must,,,,,
859,Bowel_Loops,20,General,Bladder,116 cc,139 cc,,37.5 Gy,,,,RAIDER,,Must,,,,,
860,Bowel_Loops,20,General,Bladder,104 cc,127 cc,,41.7 Gy,,,,RAIDER,,Must,,,,,
861,Bowel_Loops,20,General,Bladder,91 cc,115 cc,,45.8 Gy,,,,RAIDER,,Must,,,,,
862,Bowel_Loops,20,General,Bladder,73 cc,98 cc,,50 Gy,,,,RAIDER,,Must,,,,,
863,Bowel_Loops,20,General,Bladder,23 cc,40 cc,,54.2 Gy,,,,RAIDER,,Must,,,,,
864,Bowel_Loops,20,General,Bladder,0 cc,10 cc,,58.3 Gy,,,,RAIDER,,Must,,,,,
865,Bowel_Loops,20,General,Bladder,0 cc,,,61.7 Gy,,,,RAIDER,,Must,,,,,
866,Bowel_Loop_La,Conventional,General,,Max,,,60 Gy,,,,,,,Needs source,,,,
867,Bowel_Loop_La,1,General,,Max,,,29.2 Gy,,,,BR002,Timmerman,,,,,,
868,Bowel_Loop_La,1,General,,Max,,,18.4 Gy,,,,RTOG 0631,TG-101,,,,,,
869,Bowel_Loop_La,1,General,,20 cc,,,14.3 Gy,,,,RTOG 0631,TG-101,,,,,,
870,Bowel_Loop_La,1,General,,20 cc,,,18 Gy,,,,BR002,Timmerman,,,,,,
871,Bowel_Loop_La,3,General,,20 cc,,,24 Gy,,,,BR002,"TG-101,Timmerman",,,,,,
872,Bowel_Loop_La,3,General,,0.5 cc,,,28.2 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
873,Bowel_Loop_La,3,General,,Max,,,34.5 Gy,,,,BR002,Timmerman,,,,,,
874,Bowel_Loop_La,3,General,,1.5 cc,,,42 Gy,,,,IROCK: Solitary Kidney,,,,,,,
875,Bowel_Loop_La,5,General,,20 cc,,,25 Gy,,,,,TG-101,,,,,,
876,Bowel_Loop_La,5,General,,20 cc,,,28.5 Gy,,,,BR002,Timmerman,,,,,,
877,Bowel_Loop_La,5,General,,Max,,,40 Gy,,,,BR002,Timmerman,,,,,,
878,Bowel_Loop_La,5,General,,Max,,,38 Gy,,,,,TG-101,,,,,,
879,Bowel_Loop_La,5,General,,0.5 cc,,,32 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
880,Bowel_Loop_La,10,General,,Max,,,50.2 Gy,,,,,,,Needs source,,,,
881,Bowel_Loop_La,10,General,,20 cc,,,32.2 Gy,,,,,,,Needs source,,,,
882,Bowel_Loop_La,15-16,General,Pancreas,Max,,,50 Gy,,,,,,,Koay PRO '20,https://pubmed.ncbi.nlm.nih.gov/32061993/,,,
883,Bowel_Loop_La,20,General,,Max,,,50 Gy,,,,,NRG Prostate,,,,,,
884,Bowel_Loop_La,Conventional,General,"Anal,Rectal",200 cc,,,30 Gy,,,,RTOG 0529,,,Abraham PRO '20,https://pubmed.ncbi.nlm.nih.gov/32771626/,,,
885,Bowel_Loop_La,Conventional,General,Sarcoma,33%,,,55 Gy,,,,,,,Needs source,,,,
886,Bowel_Loop_La,Conventional,General,Sarcoma,100%,,,45 Gy,,,,,,,Needs source,,,,
887,Bowel_Loop_La,Conventional,General,Sarcoma,20 cc,,,60 Gy,,,,,,,Baldini IJROBP '15,https://www.redjournal.org/article/S0360-3016(15)00180-7/abstract,,,
888,Bowel_Loop_La,Conventional,General,"Anal,Rectal",150 cc,180 cc,,35 Gy,,,,"RTOG 0529,RTOG 0822",,,,,,,
889,Bowel_Loop_La,Conventional,General,Anal,20 cc,,,45 Gy,,,,RTOG 0529,,,,,,,
890,Bowel_Loop_La,2,General,,Max,,,20 Gy,,,,SC.24,,,,,,,
891,Sigmoid,Conventional,General,Prostate,Max,,,62.5 Gy,,,,,NRG Prostate,,,,,,
892,Sigmoid,Conventional,General,Prostate,2%,,,60 Gy,,,,,NRG Prostate,,,,,,
893,Sigmoid,28,General,Prostate,Max,,,55 Gy,,,,,NRG Prostate,,,,,,
894,Sigmoid,Conventional,General,Cervix,Max,,,105%,,,,EMBRACE II,,Must,,,,,"No 105% hot spot in bowel bag (e.g., 47.25 Gy for 45/25), or if node positive, Dmax < 105% in regions 1.0-1.5 cm outside PTV-N"
895,Rectum,Conventional,General,,15%,20%,,75 Gy,,,,"RTOG 0415,PACE",QUANTEC,,,,,,Late G3+ and G2+ of < 10% and < 15% for V75 < 15%. V70 < 20%. V65 < 25%. V60 < 35%. V50 < 50%.
896,Rectum,Conventional,General,,20%,30%,,70 Gy,,,,"RTOG 0415,PACE",QUANTEC,,Hamstra IJROBP '13,https://www.sciencedirect.com/science/article/pii/S0360301613001739?via%3Dihub,,,Late G3+ and G2+ of < 10% and < 15% for V75 < 15%. V70 < 20%. V65 < 25%. V60 < 35%. V50 < 50%.
897,Rectum,Conventional,General,,25%,40%,,65 Gy,,,,"RTOG 0415,RTOG 0815,RTOG 0534 (SPPORT)",QUANTEC,,,,,,Late G3+ and G2+ of < 10% and < 15% for V75 < 15%. V70 < 20%. V65 < 25%. V60 < 35%. V50 < 50%.
898,Rectum,Conventional,General,,50%,,,50 Gy,,,,PACE,QUANTEC,,,,,,Late G3+ and G2+ of < 10% and < 15% for V75 < 15%. V70 < 20%. V65 < 25%. V60 < 35%. V50 < 50%.
899,Rectum,Conventional,General,Gynecological,2 cc,,,65 Gy,69.5 Gy,EQD2,,,,,Mazeron RTO '16,https://www.sciencedirect.com/science/article/pii/S0167814016311549?via%3Dihub,Kircheiner RTO '16,https://www.sciencedirect.com/science/article/pii/S0167814016000025?via%3Dihub,
900,Rectum,Conventional,General,Gynecological,11 cc,,,55 Gy,,EQD2,,,,,Ujaimi BT '17,https://www.sciencedirect.com/science/article/pii/S1538472117303938?via%3Dihub,,,
901,Rectum,Conventional,General,Prostate,55%,60%,,40 Gy,,,,RTOG 0534 (SPPORT),,,,,,,
902,Rectum,1,General,,20 cc,,,14.3 Gy,22 Gy,,,"BR002,RTOG 0631","TG-101,Timmerman",,,,,,
903,Rectum,1,General,,Max,,,18.4 Gy,,,,RTOG 0631,TG-101,,,,,,
904,Rectum,1,General,,3.5 cc,,,39 Gy,,,,BR002,Timmerman,,,,,,
905,Rectum,1,General,,Max,,,44.2 Gy,,,,BR002,Timmerman,,,,,,
906,Rectum,3,General,,20 cc,,,24 Gy,27.5 Gy,,,BR002,"TG-101,Timmerman",,,,,,
907,Rectum,3,General,,3.5 cc,,,45 Gy,,,,BR002,Timmerman,,,,,,
908,Rectum,3,General,,0.5 cc,,,28.2 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
909,Rectum,3,General,,Max,,,49.5 Gy,,,,BR002,Timmerman,,,,,,
910,Rectum,5,General,,20 cc,,,25 Gy,32.5 Gy,,,BR002,"TG-101,Timmerman",,,,,,
911,Rectum,5,General,,0.5 cc,,,32 Gy,,,,,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,,,,,,
912,Rectum,5,General,Prostate,3.5 cc,,,50 Gy,,,,BR002,Timmerman,,,,,,
913,Rectum,5,General,Prostate,Max,,,55 Gy,,,,BR002,Timmerman,,,,,,
914,Rectum,5,General,Prostate,Max,,,38 Gy,,,,,TG-101,,,,,,
915,Rectum,5,General,Prostate,Max,,,38.06 Gy,40 Gy,,,NRG GU005,,,,,,,
916,Rectum,5,General,Prostate,3 cc,,,34.4 Gy,36 Gy,,,NRG GU005,,,,,,,
917,Rectum,10,General,,Max,,,50.2 Gy,,,,,,,Needs source,,,,
918,Rectum,10,General,,20 cc,,,32.2 Gy,,,,,,,Needs source,,,,
919,Rectum,Conventional,General,,25%,,,65 Gy,,,,,QUANTEC,,,,,,Late G3+ and G2+ of < 10% and < 15% for V75 < 15%. V70 < 20%. V65 < 25%. V60 < 35%. V50 < 50%.
920,Rectum,Conventional,General,,35%,55%,,60 Gy,,,,"RTOG 0415,RTOG 0815,RTOG 0534 (SPPORT)",QUANTEC,,,,,,Late G3+ and G2+ of < 10% and < 15% for V75 < 15%. V70 < 20%. V65 < 25%. V60 < 35%. V50 < 50%.
921,Rectum,Conventional,General,,60%,,,45 Gy,,,,RTOG 0724,,,,,,,Late G3+ and G2+ of < 10% and < 15% for V75 < 15%. V70 < 20%. V65 < 25%. V60 < 35%. V50 < 50%.
922,Rectum,Conventional,General,,80%,100%,,40 Gy,,,,RTOG 0418,,,,,,,
923,Rectum,Conventional,General,,60%,,,30 Gy,,,,RTOG 0418,,,,,,,
924,Rectum,20,General,,0.01%,1%,,60 Gy,,,,CHHiP,NRG Prostate,,Wilkins IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/31987974,,,
925,Rectum,20,General,,22%,,,50 Gy,,,,CHHiP,NRG Prostate,,Wilkins IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/31987974,,,
926,Rectum,20,General,,38%,,,40 Gy,,,,CHHiP,NRG Prostate,,Wilkins IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/31987974,,,
927,Rectum,20,General,,57%,,,30 Gy,,,,CHHiP,NRG Prostate,,Wilkins IJROBP '20,https://www.ncbi.nlm.nih.gov/pubmed/31987974,,,
928,Rectum,20,General,,85%,,,20 Gy,,,,,NRG Prostate,,,,,,
929,Rectum,20,General,,Circumference: Full,,,20 Gy,,,,,NRG Prostate,,,,,,
930,Rectum,Conventional,General,Prostate,10 cc,,,72 Gy,,,,,NRG Prostate,,,,,,
931,Rectum,Conventional,General,Prostate,15%,,,70 Gy,,,,,NRG Prostate,,,,,,
932,Rectum,Conventional,General,Prostate,50%,,,45 Gy,,,,,NRG Prostate,,,,,,
933,Rectum,28,General,Prostate,15%,,,74 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
934,Rectum,28,General,Prostate,25%,,,69 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
935,Rectum,28,General,Prostate,15%,,,65 Gy,,,,,NRG Prostate,,,,,,
936,Rectum,28,General,Prostate,10 cc,,,65 Gy,,,,,NRG Prostate,,,,,,
937,Rectum,28,General,Prostate,35%,,,64 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
938,Rectum,28,General,Prostate,50%,,,59 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
939,Rectum,28,General,Prostate,25%,,,55 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
940,Rectum,28,General,Prostate,45%,,,45 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
941,Rectum,28,General,Prostate,D5%,,,62 Gy,,,,"RTOG 0415,NRG GU005",,,Thor RTO '19,https://www.sciencedirect.com/science/article/pii/S0167814019300854,,,
942,Rectum,28,General,Prostate,10 cc,,,70 Gy,,,,,,,Needs source,,,,
943,Rectum,20,General,Prostate,30%,,,46 Gy,,,,PROFIT,,,,,,,
944,Rectum,20,General,Prostate,50%,,,37 Gy,,,,PROFIT,,,,,,,
945,Rectum,5,General,Prostate,Max,,,35 Gy,38 Gy,,,,HyTEC,,,,,,
946,Rectum,5,General,Prostate,10%,,,32.63 Gy,34 Gy,,,NRG GU005,,,,,,,
947,Rectum,5,General,Prostate,20%,,,29 Gy,30 Gy,,,"PACE,NRG GU005",,,,,,,
948,Rectum,5,General,Prostate,50%,,,18.1 Gy,19 Gy,,,"PACE,NRG GU005",,,,,,,
949,Rectum,Conventional,General,Cervix,Max,,,105%,,,,EMBRACE II,,Must,,,,,"No 105% hot spot in bowel bag (e.g., 47.25 Gy for 45/25), or if node positive, Dmax < 105% in regions 1.0-1.5 cm from PTV-N"
950,Rectum,Conventional,General,Cervix,75%,,,40 Gy,,,,EMBRACE II,,Can,,,,,
951,Rectum,Conventional,General,Cervix,95%,,,30 Gy,,,,EMBRACE II,,Can,,,,,
952,Rectum,Conventional,General,Bladder,80%,,,30 Gy,,,,RAIDER,,Must,,,,,
953,Rectum,Conventional,General,Bladder,60%,,,50 Gy,,,,RAIDER,,Must,,,,,
954,Rectum,Conventional,General,Bladder,50%,,,60 Gy,,,,RAIDER,,Must,,,,,
955,Rectum,Conventional,General,Bladder,30%,,,65 Gy,,,,RAIDER,,Must,,,,,
956,Rectum,Conventional,General,Bladder,15%,,,70 Gy,,,,RAIDER,,Must,,,,,
957,Rectum,20,General,Bladder,80%,,,25 Gy,,,,RAIDER,,Must,,,,,NRG prostate atlas advises to avoid full circumferential RT of rectum with 20 Gy
958,Rectum,20,General,Bladder,60%,,,41.7 Gy,,,,RAIDER,,Must,,,,,
959,Rectum,20,General,Bladder,50%,,,50 Gy,,,,RAIDER,,Must,,,,,
960,Rectum,20,General,Bladder,30%,,,54.2 Gy,,,,RAIDER,,Must,,,,,
961,Rectum,20,General,Bladder,15%,,,58.3 Gy,,,,RAIDER,,Must,,,,,
1164,Rectum,Conventional,General,Pediatrics,100%,,,45 Gy,,,,AEWS 1031,,,,,,,
962,Anus,Conventional,General,Sarcoma,50%,,,30 Gy,,,,RTOG 0630,,,,,,,
963,Bladder,Conventional,General,,25%,30%,,75 Gy,,,,"RTOG 0415,RTOG 0815",QUANTEC,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
964,Bladder,Conventional,General,,35%,40%,,70 Gy,,,,"RTOG 0415,RTOG 0815",QUANTEC,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
965,Bladder,Conventional,General,Prostate,70%,77.5%,,40 Gy,,,,RTOG 0534 (SPPORT),,,,,,,RTOG 05-34 / SPPORT allows variation acceptable if no bladder constraints are met.
966,Bladder,Conventional,General,Prostate,50%,,,50 Gy,,,,"PACE,CHHiP",,,,,,,
967,Bladder,Conventional,General,,50%,55%,,65 Gy,,,,"RTOG 0415,RTOG 0815,RTOG 0534 (SPPORT)",QUANTEC,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
968,Bladder,1,General,,15 cc,,,11.4 Gy,12 Gy,,,BR002,"TG-101,Timmerman",,,,,,
969,Bladder,1,General,,Max,,,18.4 Gy,,,,,TG-101,,,,,,
970,Bladder,1,General,,Max,,,25 Gy,,,,BR002,Timmerman,,,,,,
971,Bladder,3,General,,15 cc,,,16.8 Gy,,,,BR002,"TG-101,Timmerman",,,,,,
972,Bladder,3,General,,Max,,,28.2 Gy,,,,,TG-101,,,,,,
973,Bladder,3,General,,Max,,,33 Gy,,,,BR002,Timmerman,,,,,,
974,Bladder,5,General,,15 cc,,,18.3 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
975,Bladder,5,General,Prostate,10%,,,18.12 Gy,20 Gy,,,NRG GU005,,,,,,,
976,Bladder,5,General,,15 cc,,,20 Gy,,,,BR002,Timmerman,,,,,,
977,Bladder,5,General,,Max,,,38 Gy,,,,BR002,"TG-101,Timmerman",,,,,,
978,Bladder,5,General,Prostate,Max,,,38.06 Gy,40 Gy,,,NRG GU005,,,,,,,
979,Bladder,10,General,,Max,,,50.2 Gy,,,,,,,Needs source,,,,
980,Bladder,10,General,,15 cc,,,23 Gy,,,,,,,Needs source,,,,
981,Bladder,Conventional,General,,2 cc,,,80 Gy,,EQD2,,,,,Jensen RTO '17,https://www.thegreenjournal.com/article/S0167-8140(17)30500-5/pdf,,,
982,Bladder,Conventional,General,,15%,20%,,80 Gy,,,,"RTOG 0415,RTOG 0815",QUANTEC,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
983,Bladder,Conventional,General,,35%,70%,,45 Gy,,,,"RTOG 1203 (TIME-C),RTOG 0724",,,,,,,
984,Bladder,Conventional,General,"Rectal,Anal",35%,40%,,40 Gy,,,,"RTOG 0822,RTOG 0529",,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
985,Bladder,Conventional,General,Rectal,15%,,,45 Gy,,,,RTOG 0822,,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
986,Bladder,Conventional,General,Rectal,Max,,,50 Gy,,,,RTOG 0822,,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
987,Bladder,Conventional,General,Anal,50%,,,35 Gy,,,,RTOG 0529,,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
988,Bladder,Conventional,General,Anal,5%,,,50 Gy,,,,RTOG 0529,,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
989,Bladder,20,General,,3%,,,60 Gy,,,,,NRG Prostate,,,,,,
990,Bladder,20,General,,5%,,,56.8 Gy,,,,,NRG Prostate,,,,,,
991,Bladder,20,General,,25%,,,48 Gy,,,,,NRG Prostate,,,,,,
992,Bladder,20,General,,50%,,,40 Gy,,,,,NRG Prostate,,,,,,
993,Bladder,Conventional,General,,15%,,,70 Gy,,,,,NRG Prostate,,,,,,"Minimize late G3+ toxicity with V80 < 15%, V75 < 25%, V70 < 35%, and V65 < 50%."
994,Bladder,Conventional,General,Prostate,50%,,,45 Gy,,,,,NRG Prostate,,,,,,
995,Bladder,28,General,Prostate,10 cc,,,70 Gy,,,,,,,Needs source,,,,
996,Bladder,28,General,Prostate,15%,,,79 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
997,Bladder,28,General,Prostate,25%,,,74 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
998,Bladder,28,General,Prostate,35%,40%,,69 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
999,Bladder,28,General,Prostate,50%,55%,,64 Gy,,,,"RTOG 0415,NRG GU005",,,,,,,
1000,Bladder,28,General,Prostate,15%,,,65 Gy,,,,,NRG Prostate,,,,,,
1001,Bladder,28,General,Prostate,45%,,,45 Gy,,,,,NRG Prostate,,,,,,
1002,Bladder,28,General,Prostate,25%,,,55 Gy,,,,,NRG Prostate,,,,,,
1003,Bladder,28,General,Prostate,90%,,,35 Gy,,,,NRG GU005,,,,,,,
1004,Bladder,28,General,Prostate,35%,,,40 Gy,,,,,,,Needs source,,,,
1005,Bladder,20,General,Prostate,30%,,,46 Gy,,,,PROFIT,,,,,,,
1006,Bladder,20,General,Prostate,50%,,,37 Gy,,,,PROFIT,,,,,,,
1007,Bladder,5,General,Prostate,5 cc,10 cc,,37 Gy,,,,PACE,,,,,,,HyTEC: Rx dose allowed to 5-10 cc
1008,Bladder,5,General,Prostate,40%,,,18.1 Gy,,,,PACE,,,,,,,HyTEC: Rx dose allowed to 5-10 cc
1009,Bladder,Conventional,General,Cervix,Max,,,105%,,,,EMBRACE II,,Must,,,,,"No 105% hot spot in bladder (e.g., 47.25 Gy for 45/25), or if node positive, Dmax < 105% in regions 1.0-1.5 cm from PTV-N"
1010,Bladder,Conventional,General,Cervix,60%,,,40 Gy,,,,EMBRACE II,,Can,,,,,
1011,Bladder,Conventional,General,Cervix,80%,,,30 Gy,,,,EMBRACE II,,Can,,,,,
1147,Bladder,5,General,Rectal,40%,,,22.2 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1148,Bladder,5,General,Rectal,15%,,,25 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1149,Bladder,5,General,Rectal,Max,,,27.8 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1158,Bladder,Conventional,General,Anal,30%,,,50 Gy,,,,,,,,,,,Emma Holliday MDACC
1159,Bladder,Conventional,General,Pediatrics,100%,,,45 Gy,,,,AEWS 1031,,,,,,,
1170,Bladder,Conventional,General,Pediatrics,100%,,,45 Gy,,,,AEWS 1031,,,,,,,
1012,Ureter/Urethra,Conventional,General,,Max,,,70 Gy,,,,,,,,,,,Urethra: < 70 Gy with < 5% risk of stricture.
1013,Ureter/Urethra,1,General,,Max,,,35 Gy,,,,,Timmerman,,,,,,
1014,Ureter/Urethra,3,General,,Max,,,40 Gy,,,,BR002,"Timmerman,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
1015,Ureter/Urethra,5,General,,Max,,,45 Gy,,,,BR002,"Timmerman,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
1016,Ureter/Urethra,5,General,Prostate,50%,,,42 Gy,,,,PACE,,,,,,,
1017,Ureter/Urethra,5,General,Prostate,Max,,,38.78 Gy,43.5 Gy,,,NRG GU005,,,,,,,
1018,Ureter/Urethra,5,General,Prostate,Max,,,38 Gy,42 Gy,,,,HyTEC,,,,,,
1019,Femoral_Heads,Conventional,General,,Mean,,,45 Gy,,,,,,,Needs source,,,,
1020,Femoral_Heads,Conventional,General,Anal,50%,,,30 Gy,,,,RTOG 0529,,,,,,,
1021,Femoral_Heads,1,General,,10 cc,,,14 Gy,,,,,TG-101,,,,,,
1022,Femoral_Heads,1,General,,10 cc,,,15 Gy,,,,BR002,Timmerman,,,,,,
1023,Femoral_Heads,3,General,,10 cc,,,21.9 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,Lower vagina
1024,Femoral_Heads,3,General,,10 cc,,,24 Gy,,,,BR002,Timmerman,,,,,,Lower vagina
1025,Femoral_Heads,5,General,,10 cc,,,30 Gy,,,,BR002,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy,Timmerman",,,,,,Lower vagina
1026,Femoral_Heads,10,General,,10 cc,,,39.1 Gy,,,,,,,Needs source,,,,Lower vagina
1027,Femoral_Heads,Conventional,General,"Anal,Rectal",35%,40%,,40 Gy,,,,"RTOG 0529,RTOG 0822",,,,,,,
1028,Femoral_Heads,Conventional,General,Anal,5%,,,44 Gy,,,,RTOG 0529,,,,,,,
1029,Femoral_Heads,Conventional,General,Rectal,25%,,,45 Gy,,,,RTOG 0822,,,,,,,
1030,Femoral_Heads,Conventional,General,Rectal,Max,,,50 Gy,,,,RTOG 0822,,,Needs source,,,,
1031,Femoral_Heads,20,General,,Max,,,37 Gy,,,,,NRG Prostate,,,,,,
1032,Femoral_Heads,20,General,,5%,,,35 Gy,,,,,NRG Prostate,,,,,,
1033,Femoral_Heads,Conventional,General,Prostate,Max,,,52.5 Gy,,,,,NRG Prostate,,,,,,
1034,Femoral_Heads,Conventional,General,Prostate,2%,,,50 Gy,,,,,NRG Prostate,,,,,,
1035,Femoral_Heads,Conventional,General,Rectal,Max,,,50 Gy,,,,RTOG 0822,,,Needs source,,,,
1036,Femoral_Heads,28,General,Prostate,Max,,,52.5 Gy,,,,,NRG Prostate,,,,,,
1037,Femoral_Heads,28,General,Prostate,1%,,,50 Gy,,,,,NRG Prostate,,,,,,
1038,Femoral_Heads,28,General,Prostate,Max,,,40 Gy,,,,NRG GU005,,,,,,,
1039,Femoral_Heads,20,General,Prostate,0.5%,,,43 Gy,,,,PROFIT,,,,,,,
1040,Femoral_Heads,5,General,Prostate,10 cc,,,19.9 Gy,,,,NRG GU005,,,,,,,Lower vagina
1041,Femoral_Heads,5,General,Prostate,1 cc,,,15.6 Gy,,,,NRG GU005,,,,,,,Lower vagina
1042,Femoral_Heads,5,General,Prostate,5%,,,14.5 Gy,,,,PACE,,,,,,,Lower vagina
1043,Femoral_Heads,Conventional,General,Sarcoma,5%,,,60 Gy,,,,RTOG 0630,,,Needs source,,,,
1044,Femoral_Heads,Conventional,General,Sarcoma,Max,,,59 Gy,,,,,,,Dickie IJROBP '09,https://www.sciencedirect.com/science/article/pii/S0360301608038546?via%3Dihub,Casey ASO '20,https://pubmed.ncbi.nlm.nih.gov/33073343/,
1045,Femoral_Heads,Conventional,General,Sarcoma,Mean,,,37 Gy,,,,,,,Dickie IJROBP '09,https://www.sciencedirect.com/science/article/pii/S0360301608038546?via%3Dihub,Casey ASO '20,https://pubmed.ncbi.nlm.nih.gov/33073343/,
1046,Femoral_Heads,Conventional,General,Sarcoma,64%,,,40 Gy,,,,,,,Dickie IJROBP '09,https://www.sciencedirect.com/science/article/pii/S0360301608038546?via%3Dihub,Casey ASO '20,https://pubmed.ncbi.nlm.nih.gov/33073343/,
1047,Femoral_Heads,Conventional,General,Pediatrics,Mean,,,25 Gy,,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,,,At risk for SCFE
1048,Femoral_Heads,Conventional,General,Pediatrics,Mean,,,30 Gy,40 Gy,,,,,,ILROG Guidelines for Peds,https://www.sciencedirect.com/science/article/pii/S1879850014001179?via%3Dihub,,,At risk for AVN
1049,Femoral_Heads,Conventional,General,,50%,,,30 Gy,,,,RTOG 0529,,,,,,,
1050,Femoral_Heads,Conventional,General,Gynecological,15%,,,30 Gy,,,,RTOG 0418,,,,,,,
1051,Femoral_Heads,Conventional,General,Rectal,40%,,,40 Gy,,,,RTOG 0822,,,,,,,
1052,Femoral_Heads,Conventional,General,,10%,,,50 Gy,,,,RTOG 0534 (SPPORT),,,,,,,
1053,Femoral_Heads,Conventional,General,Bladder,50%,,,50 Gy,,,,RAIDER,,Must,,,,,
1054,Femoral_Heads,20,General,Bladder,50%,,,41.7 Gy,,,,RAIDER,,Must,,,,,
1150,Femoral_Heads,5,General,Rectal,40%,,,22.2 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1151,Femoral_Heads,5,General,Rectal,15%,,,25 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1152,Femoral_Heads,5,General,Rectal,Max,,,27.8 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1055,Iliac_Crest,Conventional,General,,50%,,,30 Gy,,,,RTOG 0529,,,,,,,Lower vagina
1056,Iliac_Crest,Conventional,General,Anal,35%,,,40 Gy,,,,RTOG 0529,,,,,,,Lower vagina
1057,Iliac_Crest,Conventional,General,Anal,5%,,,50 Gy,,,,RTOG 0529,,,,,,,Lower vagina
1058,Pubic_Bone,Conventional,General,Prostate,25%,,,70 Gy,,,,,NRG Prostate,,,,,,
1059,Pubic_Bone,28,General,Prostate,30%,,,60 Gy,,,,,NRG Prostate,,,,,,
1060,Pubic_Bone,20,General,Prostate,20%,,,57 Gy,,,,,NRG Prostate,,,,,,
1061,Bone_Marrow,Conventional,General,Gynecological,Median,,,34.2 Gy,,,,RTOG 0418,,,Klopp IJROBP '16,https://pubmed.ncbi.nlm.nih.gov/23582248/,,,G2+ heme for BM V40 ± 37% or median BM ± 34.2 Gy of 40→ 75%
1062,Bone_Marrow,Conventional,General,Gynecological,37%,60%,,40 Gy,,,,"RTOG 0418,RTOG 1203 (TIME-C)",,,,,,,G2+ heme for BM V40 ± 37% or median BM ± 34.2 Gy of 40→ 75%
1063,Bone_Marrow,Conventional,General,Cervix,75%,,,20 Gy,,,,,,,Mell IJROBP '06,https://pubmed.ncbi.nlm.nih.gov/16757127/,,,G2+ neutropenia for BM V10 ± 90% of 11→ 74% and BM V20 ± 75% of 14→ 25%
1064,Bone_Marrow,Conventional,General,Gynecological,90%,,,10 Gy,25 Gy,,,"RTOG 0418,RTOG 1203 (TIME-C)",,,Mell IJROBP '06,https://pubmed.ncbi.nlm.nih.gov/16757127/,,,G2+ neutropenia for BM V10 ± 90% of 11→ 74% and BM V20 ± 75% of 14→ 25%
1065,Bone_Marrow,Conventional,General,Anal,750 cc,,,30 Gy,,,,,,,Lee IJROBP '17,https://pubmed.ncbi.nlm.nih.gov/28068238/,,,
1066,Bone_Marrow,Conventional,General,Anal,23%,,,40 Gy,,,,,,,Lee IJROBP '17,https://pubmed.ncbi.nlm.nih.gov/28068238/,,,"It makes sense that V40 is a lower value than for anal cancer as cervical cancer, as MMC has significant heme toxicity."
1067,Joint/Bone,Conventional,General,Sarcoma,50%,,,50 Gy,,,,RTOG 0630,,,Lee IJROBP '17,https://pubmed.ncbi.nlm.nih.gov/28068238/,,,Soft tissue growth and development affected at 25-30 Gy. 
1068,Penile_Bulb,Conventional,General,,Mean,,,52.5 Gy,,,,"RTOG 0415,RTOG 0815",QUANTEC,,,,,,Mean dose < 52.5 Gy and prostate V50 < 90% is associated with a < 35% incidence of severe ED. 
1069,Penile_Bulb,Conventional,General,,60%,70%,,70 Gy,,,,,QUANTEC,,,,,,Penile bulb V70 < 60-70% is associated with a < 55% incidence of severe ED.
1070,Penile_Bulb,Conventional,General,,90%,95%,,50 Gy,,,,,QUANTEC,,,,,,Mean dose < 52.5 Gy and prostate V50 < 90% is associated with a < 35% incidence of severe ED. 
1071,Penile_Bulb,Conventional,General,Prostate,Mean,,,24 Gy,,,,CHHiP,,,Murray CTRO '19,https://pubmed.ncbi.nlm.nih.gov/32072028/,,,
1072,Penile_Bulb,1,General,,Max,,,34 Gy,,,,,TG-101,,,,,,
1073,Penile_Bulb,1,General,,3 cc,,,14 Gy,16 Gy,,,BR002,"TG-101,Timmerman",,,,,,
1074,Penile_Bulb,3,General,,3 cc,,,21.9 Gy,25 Gy,,,BR002,"TG-101,Timmerman",,,,,,
1075,Penile_Bulb,3,General,,Max,,,42 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
1076,Penile_Bulb,3,General,,Max,,,40 Gy,,,,,Timmerman,,,,,,
1077,Penile_Bulb,5,General,,3 cc,,,30 Gy,,,,BR002,"TG-101,Timmerman,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
1078,Penile_Bulb,5,General,,Max,,,50 Gy,,,,,"TG-101,UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy",,,,,,
1079,Penile_Bulb,10,General,,Max,,,67 Gy,,,,,,,Needs source,,,,
1080,Penile_Bulb,10,General,,3 cc,,,39.1 Gy,,,,,,,Needs source,,,,
1081,Penile_Bulb,20,General,Prostate,50%,,,22 Gy,,,,,NRG Prostate,,,,,,
1082,Penile_Bulb,Conventional,General,Prostate,50%,,,50 Gy,,,,,NRG Prostate,,,,,,
1083,Penile_Bulb,28,General,Prostate,Mean,,,51 Gy,,,,,NRG Prostate,,,,,,
1084,Penile_Bulb,28,General,Prostate,ALARA,,,ALARA,,,,,NRG Prostate,,,,,,
1085,Penile_Bulb,5,General,Prostate,Max,,,36.25 Gy,,,,NRG GU005,,,,,,,
1086,Penile_Bulb,5,General,Prostate,3 cc,,,19.9 Gy,,,,NRG GU005,,,,,,,
1087,Penile_Bulb,5,General,Prostate,50%,,,29.5 Gy,,,,PACE,,,,,,,
1088,Vagina,Conventional,General,,Max,,,120 Gy,150 Gy,,,,,,Kirchheiner RTO '16,https://www.sciencedirect.com/science/article/pii/S0167814016000025?via%3Dihub,,,Upper vagina; Vaginal doses >50-60 Gy can cause significant fibrosis. 
1089,Vagina,Conventional,General,,Max,,,80 Gy,90 Gy,,,,,,Kirchheiner RTO '16,https://www.sciencedirect.com/science/article/pii/S0167814016000025?via%3Dihub,,,Mid vagina; Vaginal doses >50-60 Gy can cause significant fibrosis. 
1090,Vagina,Conventional,General,,Max,,,60 Gy,70 Gy,,,,,,Kirchheiner RTO '16,https://www.sciencedirect.com/science/article/pii/S0167814016000025?via%3Dihub,,,Lower vagina; Vaginal doses >50-60 Gy can cause significant fibrosis. 
1091,Vagina,1,General,,10 cc,,,14 Gy,,,,,TG-101,,,,,,
1092,Vagina,1,General,,10 cc,,,15 Gy,,,,BR002,Timmerman,,,,,,
1093,Vagina,Conventional,General,,Max,,,60 Gy,70 Gy,,,,,,Kirchheiner RTO '16,https://www.sciencedirect.com/science/article/pii/S0167814016000025?via%3Dihub,,,Lower vagina; Vaginal doses >50-60 Gy can cause significant fibrosis. 
1094,Vulva,Conventional,General,Sarcoma,50%,,,30 Gy,,,,,,,,,,,
1095,External_Genitalia,Conventional,General,Anal,50%,67%,,20 Gy,,,,RTOG 0529,,,,,,,
1096,External_Genitalia,Conventional,General,Anal,20%,35%,,30 Gy,,,,RTOG 0529,,,,,,,
1097,External_Genitalia,Conventional,General,Anal,5%,,,40 Gy,,,,RTOG 0529,,,,,,,
1098,Testes,Conventional,General,Sarcoma,50%,,,3 Gy,,,,,,,,,,,
1099,Gluteal_Folds,Conventional,General,"Rectal,Anal",Max,,,36 Gy,,,,,,Can,,,,,
1100,Transposed_Ovaries,Conventional,General,Gynecological,Mean,,,5 Gy,8 Gy,,,EMBRACE II,,Must,,,,,
1101,Transposed_Ovaries,Conventional,General,Gynecological,29.65%,,,5.5 Gy,,,,,,,Yin Rad Onc '19,https://ro-journal.biomedcentral.com/articles/10.1186/s13014-019-1312-2#Sec3,,,
1102,PTV,5,General,Breast,95%,,,95%,,,,UK FAST-Forward,,,,,,,
1103,PTV,5,General,Breast,5%,,,105%,,,,UK FAST-Forward,,,,,,,
1104,PTV,5,General,Breast,2%,,,107%,,,,UK FAST-Forward,,,,,,,
1105,PTV,5,General,Breast,Max,,,110%,,,,UK FAST-Forward,,,,,,,
1106,PTV,5,General,Breast,Partial,,,,,,,Florence,,,,,,,"CTV + 1 cm, allowed 4 mm to lung and 3 mm from skin."
1107,PTV,5,General,Breast,Max,,,105%,110%,,,Florence,,,,,,,
1108,PTV,5,General,Breast,95%,,,30 Gy,,,,Florence,,,,,,,
1109,PTV,5,General,Breast,99%,,,28.5 Gy,,,,Florence,,,,,,,
1110,PTV,10,General,Breast,Partial,,,,,,,,,,MSKCC Braunstein IJROBP '19,https://www.sciencedirect.com/science/article/pii/S0360301619303062?via%3Dihub,,,PTV_40 = CTV + 0.5 - 1.0 cm. Subtract 0.5 cm from skin and CW (PTV volume < 35% of whole breast volume).
1111,PTV,28,General,Prostate,D0.03,,,77 Gy,80.5 Gy,,,"NRG GU005,RTOG 0415",,,,,,,
1112,PTV,28,General,Prostate,D99%,,,65.1 Gy,70 Gy,,,"NRG GU005,RTOG 0415",,,,,,,
1113,PTV,28,General,Prostate,D98%,,,66.5 Gy,70 Gy,,,"NRG GU005,RTOG 0415",,,,,,,
1114,PTV,20,General,Prostate,D99%,,,57 Gy,,,,PROFIT,,,,,,,
1115,PTV,20,General,Prostate,D1cc,,,63 Gy,,,,PROFIT,,,,,,,
1116,PTV,20,General,Prostate,D0.03,,,38.78 Gy,43.5 Gy,,,"PACE,NRG GU005",,,,,,,
1117,PTV,20,General,Prostate,D99%,,,33.7 Gy,34.4 GY,,,"PACE,NRG GU005",,,,,,,
1118,PTV,20,General,Prostate,D98%,,,34.4 Gy,36.25 Gy,,,"PACE,NRG GU005",,,,,,,
1119,PTV,Conventional,General,Cervix,95%,,,42.75 Gy,95%,,,EMBRACE II,,Must,,,,,
1120,PTV,Conventional,General,Cervix,Max,,,48.15 Gy,107%,,,EMBRACE II,,Must,,,,,"For node positive disease, limit Dmax < 107% to helper structure (PTV45-(PTVn + 1 cm))"
1121,PTV,Conventional,General,Cervix,90%,,,99%,,,,EMBRACE II,,Must,,,,,UCSD Cervix
1122,PTV,Conventional,General,Cervix,99%,,,90%,,,,EMBRACE II,,Must,,,,,UCSD Cervix
1123,PTV,Conventional,General,Cervix,97%,,,97%,,,,EMBRACE II,,Must,,,,,UCSD Cervix
1124,PTV,Conventional,General,Cervix,1%,,,115%,,,,EMBRACE II,,Must,,,,,UCSD Cervix
1125,PTV,Conventional,General,Cervix,10%,,,110%,,,,EMBRACE II,,Must,,,,,UCSD Cervix
1126,PTV,Conventional,General,Bladder,D98%,,,90%,95%,,,RAIDER,,Must,,,,,
1127,PTV,20,General,Bladder,D98%,,,90%,95%,,,RAIDER,,Must,,,,,
1153,PTV,5,General,Rectal,93%,100%,,23.25 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1154,PTV,5,General,Rectal,10%,,,26.25 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1155,PTV,5,General,Rectal,5%,,,27.5 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1156,PTV,5,General,Rectal,Max,,,28.75 Gy,,,,,,,Fields ARO '19,https://pubmed.ncbi.nlm.nih.gov/31673654/,,,
1128,ITV,Conventional,General,Cervix,Min,,,42.75 Gy,95%,,,EMBRACE II,,Must,,,,,
1129,CTV,5,General,Breast,Partial,,,,,,,Florence,,,,,,,Clips + 1 cm (3 mm cropped from skin)
1130,CTV,5,General,Breast,98%,,,30 Gy,,,,Florence,,,,,,,
1131,CTV,10,General,Breast,Partial,,,,,,,,,,MSKCC Braunstein IJROBP '19,https://www.sciencedirect.com/science/article/pii/S0360301619303062?via%3Dihub,,,CTV_40 = Cavity + 1-1.5 cm cropped at anterior surface of pec major.
1132,CTV,28,General,Prostate,D99%,,,66.5 Gy,70 Gy,,,"NRG GU005,RTOG 0415",,,,,,,
1133,CTV,20,General,Prostate,D99%,,,60 Gy,,,,PROFIT,,,,,,,
1134,PTVn,Conventional,General,Cervix,D98%,,,90%,,,,EMBRACE II,,Must,,,,,
1135,PTVn,Conventional,General,Cervix,Max,,,107%,,,,EMBRACE II,,Must,,,,,
1136,CTVn,Conventional,General,Cervix,D98%,,,100%,,,,EMBRACE II,,Must,,,,,
1137,CTVn,Conventional,General,Cervix,D50%,,,102%,,,,EMBRACE II,,Can,,,,,
1138,Conformality,Conventional,General,Cervix,1.10,,,43 Gy,,,,EMBRACE II,,Can,,,,,V43/Volume of PTV
1139,Conformality,Conventional,General,Cervix,1.55,,,36 Gy,,,,EMBRACE II,,Can,,,,,V36/Volume of PTV
1177,PTV_Breast/CW,Conventional,General,Breast,95%,,,45 Gy,47.5 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
1182,PTV_Breast/CW,Conventional,General,Breast,50%,,,54 Gy,56 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT; only applies if boost
1183,PTV_Breast/CW,Conventional,General,Breast,30%,35%,,60 Gy,,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT; only applies if boost
1178,PTV_Axilla,Conventional,General,Breast,95%,,,45 Gy,47.5 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
1180,PTV_SCV,Conventional,General,Breast,95%,,,45 Gy,47.5 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT
1181,PTV_IMN,Conventional,General,Breast,90%,,,40 Gy,45 Gy,,,,,,Bazan IJROBP '20,https://www.redjournal.org/article/S0360-3016(20)31446-2/abstract,,,Breast VMAT